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BRAF mutant colorectal cancers (CRC) mostly arise via an alternate 
pathway distinguished from the classical adenoma-carcinoma sequence involving 
APC and KRAS mutations. BRAF-driven tumors have an increased incidence of 
promoter CpG island methylator phenotype (CIMP)-high, microsatellite instable 
(MSI) phenotype, lack of concurrent mutations of APC, mucinous histology, and 
location on the right side of the colon. Although these characteristics are 
constantly observed in BRAF mutant CRCs, how this BRAF mutation induces this 
type of tumor is not clear.  
To understand this, we modeled the early carcinogenesis of colorectal 
cancer by inducing BRAFV600E and KRASG12D individually in organoids prepared 
from mouse proximal colon and subsequently determined the genome-wide gene 
expression, DNA methylation, and genetic changes in combination with growth 
properties and induction of tumor formation.  
The BRAFV600E, but not KRASG12D, mutations induced various features of 
progressive transformation consisting of increased spheroid formation of the 
organoids with internal dysplastic polypoid growth. BRAFV600E organoids 
acquired an ability to grow without stem cell niche factors such as Wnt3a, R-
Spondin and Noggin. These above phenotypic changes are phenocopies of APC 
mutations in organoids wherein the Wnt pathway is activated. Indeed, BRAFV600E 
drives sustained up-regulation of Wnt targets and stem cell genes and 
suppression of differentiation genes regardless of whether niche factors are 
added. Furthermore, in some of the transformed organoids, sequencing revealed 
	 iii	
mutations in b-catenin. Finally, and most excitingly, induction of BRAFV600E, but 
not KRASG12D, induced complete transformation forming xenograft tumors in 
immunodeficient mice. The tumors exhibit histological characteristics of 
mucinous adenocarcinoma, which is highly associated with the BRAFV600E 
mutation in human CRCs. In addition, analyses of genome-wide methylation 
revealed increased DNA methylation in CpG island promoters of many genes 
including Wnt negative regulators such as Sfrp1, Sfrp2, Wt1 and Sox17 and CIMP 
genes including p16 and Igfbp7 in the BRAFV600E mutant organoids.  
In conclusion, mouse colon organoids expressing BRAFV600E recapitulate 
features of the human right-sided CRC phenotype with adoption of a stem cell 
niche factor independency, activation of the Wnt pathway, induction of CpG 
island methylation in Wnt negative regulators and CIMP panel genes, and 
activating Wnt-pathway mutations. 
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All the work presented in this dissertation is based on the experiments and 
analysis conducted in Baylin/Easwaran laboratory at the Sidney Kimmel 
Comprehensive Cancer Center of Johns Hopkins University School of Medicine 
or in collaboration with other core laboratories in Johns Hopkins University.  
The project originally consisted of three parts: in vitro, ex vivo and in vivo 
modeling of colorectal cancer (CRC) by engineering mouse colon organoids with 
BRAFV600E or KRASG12D mutations.  This above ex vivo modeling is thus revealed 
to be an excellent system to study early events of tumorigenesis for CRC. I 
successfully induced mutations, BRAFV600E and KRASG12D separately, in colon 
organoids and analyzed their phenotypes and molecular changes including gene 
expression and DNA methylation. Most of the work presented in this dissertation 
is based on the physiological and pathological phenotyping and molecular 
characterization of the mutant organoids.  
Although most of the techniques used here pertain to growth of organoids , 
our phenotyping and molecular analyses of these were adopted from previously 
published articles and shared information from our collaborators, I modified 
their techniques to meet the objectives of this project. I hope the methods 
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Chapter 1. Introduction 
 
1.1 Cancer genetics and epigenetics 
Cancer is a result of abnormal regulation of normal processes such as 
proliferation, cellular death, genome maintenance, angiogenesis, cellular 
metabolism and immune surveillance (Hanahan and Weinberg, 2011). The 
abnormal regulation of these processes gives the cancerous cells a selective 
advantage over normal cells in growth, survival and evasion from immune 
surveillance and allows for malignant progression. All of these abnormalities are 
direct or indirect results of genetic and epigenetic changes that cause loss of 
function for tumor suppressor genes( TSGs) and genome surveillance genes and 
activation of oncogenes(OCGs).  
Genetic alterations are common causes of loss of function for TSGs and 
activation of oncogenes. Genetic alterations causing activation of oncogenes 
include gene amplification, activating missense point mutations, and 
translocation which causes formation of fusion proteins that induce 
inappropriate gene activation. In contrast, inactivating missense or nonsense 
point mutations and deletions of chromosome regions are common genetic 
alterations that cause loss of TSGs such as genome surveillance genes, cell cycle 
checkpoints and cell death related genes. In recent sequencing studies of 3284 
tumors, a total 125 driver mutations were discovered based on mutation 
frequencies (Vogelstein et al., 2013). Genes with the driver mutations are 
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involved in 12 pathways that regulate three core cellular processes including cell 
fate, cell survival and genome maintenance (Vogelstein et al., 2013).  
Another important way of losing TSGs function and activation of  
oncogenes is epigenetic alteration in the cancer genome. Although genetic 
alterations have traditionally been viewed as the main driver of cancer 
development, recently the paradigm has now been expanded to incorporate the 
disruption of epigenetic regulatory mechanisms (Baylin and Bestor, 2002; Baylin 
and Jones, 2011; Baylin and Ohm, 2006; You and Jones, 2012). Gene silencing of 
TSGs through promoter hypermethylation is a common form of epigenetic 
disruption in cancer (Baylin and Jones, 2011). For instance, genes controlling the 
cell cycle and DNA repair, such as RB, BRCA1/2, and PTEN, are known to have 
abnormal promoter region DNA methylation and associated abnormal gene 
silencing as well as undergoing mutations and deletions in cancer  
(Hatziapostolou and Iliopoulos, 2011). In addition, histone modification and 
nucleosome remodeling are other important epigenetic regulations that can be  
disrupted in cancer. Histone modifications at specific amino acid residues in gene 
regulatory regions can normally help control gene activation or repression. For 
instance, trimethylated H3 at lysine 4 is enriched in active gene promoters. In 
contrast, Trimethylated H3 at lysine 27 or trimethylation H3 at lysine 9 are 
enriched in inactive promoters (Arnold et al., 2016; Baylin and Jones, 2011; 
Hatziapostolou and Iliopoulos, 2011). These modifications are regulated by 
histone acetyltransferases, deacetylases methyltransferases and demethylases. 
Nucleosome remodeling is another key mechanism for regulation of gene 
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expression. As more and more mutations are discovered in the nucleosome 
remodeling proteins in cancers, the importance of their role in tumorigenesis is 
increasing(Bhattacharjee et al., 2016; Biegel et al., 2014; Geng et al., 2016; He et 
al., 2016; Huang et al., 2015; Kadoch and Crabtree, 2015; Levin et al., 2015; 
Malonia et al., 2014; Mayes et al., 2014; Nio et al., 2015; Oike et al., 2013; Pfister 
et al., 2015; Soshnikova et al., 2016; Wang et al., 2016; Wu et al., 2016a; Wu et al., 
2016b; Wu et al., 2014; Xu et al., 2015; Zhang et al., 2016a; Zhang et al., 2016b; 
Zollner et al., 2015). However, the direct role in tumorigenesis is still unknown.   
 
1.2  Specific genetics and epigenetics  of colorectal cancer  
It is estimated that 1.3 million persons in the world will be found to have 
colorectal cancer (CRC) in 2012. CRC is the third most common cancer in men 
and the second most in women (Arnold et al., 2016). It is also one of the most 
well studied cancers in terms of clinical, pathological and molecular 
characteristics. Although, in many instances, it is regarded as a single entity, 
CRCs are quite heterogeneous. There have been many efforts to separate CRCs 
into different types based on molecular or morphological features. For genetic 
changes, driver mutation status such as KRAS, BRAF, and APC, chromosomal 
instability and frequent mutations for repeat sequences (microsatellite instability) 
have been frequently used. For epigenetic changes, a phenotype wherein many 
genes undergo abnormal promote CpG island methylation known as the CpG 
island Methylator Phenotype (CIMP) has been appreciated since the studies of 
Minoru Toyota and colleagues (Toyota et al., 1999). These above genetic and 
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epigenetic features allow us to divide CRCs into the following 5 groups although 
the distinction is not always clear-cut due to the presence of some CRCs with 
mixed features, (Jass, 2007):  
Group 1 (12%)- CIMP-high, MLH1 methylation, Microsatellite instability 
(MSI)-high. Chromosomal instability (CIN)-negative and frequent BRAF 
mutations. 
Group 2 (8%)- CIMP-high, partial MLH1 methylation, Microsatellite 
stable or MSI-low, CIN-negative and BRAF mutations. 
Group 3 (20%)- CIMP-low, MGMT methylation, MSS or MSI-low, CIN 
positive, and KRAS mutation.  
Group 4 (57%)- CIMP-negative, MSS, CIN, APC and KRAS mutation. 
Group 5 (3%)- CIMP-negative, MSI-H, CIN-negative and mutations in 
DNA mismatch repair genes (can occur as a genetic disorder in families termed 
the Lynch syndrome) and APC mutations.  
Group 1 and 2 CRC tumors share the same precursor lesions, 
morphological features and anatomic location: serrated polyps, mucinous 
morphology, and occurrence on the right side of the colon. Group 5 tumors also 
occur predominantly on the right side but have adenoma as a precursor lesions 
and are rarely mucinous. Group 3 tumors have either serrated polyps or 
adenomas as precursor lesions and mostly occur on left side. Group 4 
predominantly develop from adenoma on left side and are rarely mucinous 
(Figure 1.1).  
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As the most prevalent tumor type in colon, group 4 tumors were subjected 
to early sequencing efforts by Bert Vogelstein and colleagues and their studies 
documented sequential accumulation of mutations such as APC, RAS, PI3K and 
TGF-β in a paradigm commonly known as the Vogelgram (Jones et al., 2008). 
Group 1, 2 and 3 CRC, which are the main object of this thesis, were classified in 
later studies, and their origins in serrated precursor lesions were proposed 
(Bettington et al., 2013; Burnett-Hartman et al., 2013; Ensari et al., 2010; Inoue 
et al., 2015; Kambara et al., 2004; Kriegl et al., 2011; Li and Burgart, 2007; 
Makinen, 2007; Michalopoulos and Tzathas, 2013; Minoo et al., 2007; 
Mohammadi et al., 2013; Murakami et al., 2015; O'Brien et al., 2006; Sakai et al., 
2016; Snover, 2011; Spring et al., 2006; Vakiani and Yantiss, 2009; Yang et al., 
2004). Although recent studies with early serrated lesions discovered that BRAF 
mutation precedes accumulation of DNA methylation in group 1 and 2 (Hinoue et 
al., 2009), the exact sequential changes remain to be elucidated.  
Among CRC subtypes, groups 1 and 5 have the best prognosis (Bettington 
et al., 2013; Ensari et al., 2010; Kriegl et al., 2011; Li and Burgart, 2007; Snover, 
2011; Spring et al., 2006). In turn, this correlates with having a high MSI status 
and high number of infiltrating lymphocytes (Pai et al., 2012). It is suggested that 
MSI causes high mutation burden and the mutations themselves or neo-antigens 
from the mutated genes induce the immune reaction and cause infiltration of 
lymphocytes (Bettington et al., 2013; Ensari et al., 2010; Kriegl et al., 2011; Li and 
Burgart, 2007; Snover, 2011; Spring et al., 2006). It has also been recently shown 
that this mutational burden and lymphocyte infiltration scenario correlates with 
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better response to immune checkpoint blockade with Pembrolizumab (Anti-PD-1) 
(Le et al., 2015). In contrast, group2 tumors seem to have the worst prognosis. 
They tend to have less lymphocyte infiltration and poor differentiation and be 
more invasive (Bettington et al., 2013; Ensari et al., 2010; Kriegl et al., 2011; Li 
and Burgart, 2007; Snover, 2011; Spring et al., 2006).  
 
1.3 Stem cell and Wnt in colorectal cancer  
In humans the entire intestinal lining epithelium is replaced every 5 to 7 
days (Basu et al., 2016). This rapid replacement is fueled by the proliferation of 
stem cells at the base of crypt and subsequent differentiation of progenies of 
these cells as they migrate upward toward the intestinal lumen where they 
undergo apoptosis. This cellular turnover enables normal homeostasis of the 
intestine (Basu et al., 2016). The normal process of proliferation and 
differentiation of intestinal stem cells is governed by a gradient of Wnt signaling 
(Basu et al., 2016) which is the strongest at the crypt base and gradually 
decreases toward the luminal side. The strong Wnt signaling supports stem cell 
maintenance and proliferation at the crypt base and the decreasing Wnt signaling 
along the crypt supports epithelial differentiation of stem cells (Basu et al., 2016).  
Cancer stem cells in colorectal cancers are suggested to have a similar role 
as intestinal stem cells in giving rise to progenitors that populate the majority of 
the tumor cells. Two models have been proposed to describe the origin of cancer 
stem cells in CRCs: the top-down and the bottom up model (Basu et al., 2016). 
The top-down model suggests that differentiated epithelial cells re-acquire stem 
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cell-like properties through hyperactivation of Wnt signaling and form aberrant 
crypt foci. On the other hand, the bottom-up model proposes that stem cells at 
the crypt base acquire ability to migrate upward without normal differentiation 
through Wnt hyperactivation. Although the suggested origin of cancer is different, 
both models require Wnt activation in either differentiated cells or stem cells. 
The importance of Wnt signaling in CRC tumorigenesis was recently 
demonstrated by formation of tumors by loss of APC and regression of tumors by 
restoration of APC even with retention of other oncogenic mutations such as 
KRAS and p53 (Basu et al., 2016; Dow et al., 2015; Guerrero-Preston et al., 2014; 
Jorissen et al., 2015; Matano et al., 2015; Pronobis et al., 2015; Strum, 2016; 
Zachos et al., 2016). Also, in model systems, Wnt suppression by expression of a 
Wnt antagonist protein HoxA5 in colon cancer cells also suppresses tumor 
growth and metastatic progression (Ordonez-Moran et al., 2015).  
 In CRCs, Wnt pathway activation can occur through genetic and 
epigenetic alterations in various components of the Wnt regulatory pathway 
(Basu et al., 2016; Dow et al., 2015; Guerrero-Preston et al., 2014; Jorissen et al., 
2015; Matano et al., 2015; Pronobis et al., 2015; Strum, 2016; Zachos et al., 2016). 
Germline mutations of APC cause familial adenomatous polyposis and 
approximately 70-80% of sporadic CRCs also harbor APC mutations or deletions. 
APC is a major binding partner and regulator of the canonical Wnt signaling 
pathway. In the absence of Wnt ligand, APC forms a destruction complex with the 
scaffold protein Axin to promote subsequent phosphorylation of b-catenin by 
Casein kinase1(CK1) and Glycogen synthase kinase 3 beta(GSK3b) (Fearon, 2011). 
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The phosphorylation of b-catenin leads to its degradation by the ubiquitin 
proteasome pathway. In the presence of Wnt ligand, the destruction complex 
disintegrates when there is recruitment of Axin protein and GSK3b to a cognate 
Wnt receptor complex consisting of the Frizzled and lipoprotein receptor-related 
protein (Fearon, 2011). The disruption of this destruction complex will lead to 
accumulation of b-catenin in the cytoplasm and its localization to the nucleus 
where it activates Wnt target gene expression along with co-activators such as 
CBP/p300 (Figure 1.2). In the case of APC mutations or deletion, the b-catenin is 
accumulated regardless of the presence of Wnt ligand due to failure of proper 
formation of the destruction complex. Mutations in other components of Wnt 
pathway including Axin, b-catenin and TCF4 are also reported in CRCs. However, 
their functional role in tumorigenesis remains to be elucidated (Fearon, 2011).  
An epigenetic change such as the abnormal promoter region DNA 
methylation, discussed earlier, can also play important role in activation of Wnt 
in CRCs. Occasionally, this occurs for APC (Arnold et al., 2004; Coyle et al., 2007; 
Erdem et al., 2014; Fu et al., 2009; Furlan et al., 2014; Haluskova et al., 2015; 
Hiltunen et al., 1997; Jin et al., 2001; Juhlin et al., 2010; Segditsas et al., 2008; 
Sievers et al., 2006; Wang et al., 2009; Zhang et al., 2007; Zhang et al., 2008). 
Also, extremely frequently in colon polyps and CRCs, such abnormal DNA 
methylation occurs in the promoter regions of the Wnt antagonists, SFRP1, 
SFRP2, SFRP5, DKK2, WIF1 and SOX17 in the transition from normal to 
colorectal cancers (Murakami et al., 2015; Silva et al., 2014). SFRP2 and SOX17 
themselves are Wnt target genes which normally can work as a negative feedback 
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loop for the Wnt pathway (Silva et al., 2014) (Figure 1.2). The suppression of all 
of these genes through DNA methylation is proposed to disrupt the negative 
feedback loop and induce hyperactivation of the Wnt pathway. The increase in 
DNA methylation has been associated with Wnt activity in CRC (Silva et al., 
2014).  
 
1.4 Organoids as an ex vivo model of gastrointestinal pathology 
Model systems have been the centerpiece of biomedical and biological 
research being used to recapitulate biological and pathological processes. Animal 
models are the most close recapitulation of human biology and pathology, but 
these can be limited by having a confounding variability and limited accessibility 
for imaging and molecular assays. Although 2D monolayer cultures have their 
advantages and have played a critical role in modern advancement of biomedical 
and biological research, they often lack proper cell to cell and cell to matrix 
interactions and hierarchal organization. More importantly, most 2D cultures are 
either cancer or transformed cell wherein the genome and epigenome have 
already undergone significant changes. Early 3D culture systems such as cell 
spheroid cultures also lack the hierarchal organization of stem cell and progenitor 
cells and thus are unable to have both ongoing self renewal and differentiation 
processes (Date and Sato, 2015). Thus, although the animal models, 2D cell 
culture and early 3D cell culture have been very important tools for discovery so 
far, they don’t cover the gap between the cellular level and the organ level.   
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The recently developed methodology by Clevers and colleagues to use stem 
cell derived organoids as a model will potentially, and robustly fill the gap. The 
model, wherein mouse and human cells, best studied to date as below from 
intestine, closely recapitulates a renewing cell system wherein, crypt stem cells, 
differentiation of their progeny, and apoptosing cells filling a lumen-like 
structure are all represented(Sato et al., 2009; Visvader and Clevers, 2016). 
Organoids recapitulate the hierarchal organization, cell-cell interaction, and cell-
matrix interaction and have the capacity for both self-renewal and differentiation. 
While a wide variety of organoids have been generated including brain, lung, liver 
and intestine, the intestinal organoid system is one of the most well established 
and most widely used system currently. Evans et al.(1994) firstly cultured 
primary adult intestinal crypt in collagen type I –coated tissue culture vessels 
(Date and Sato, 2015; Evans et al., 1994). However, the culture was good for 1-2 
weeks. Later, long lasting culture of neonatal intestinal mucosa mixed with 
mesenchymal fibroblasts was developed as an air-liquid interface culture in 2009 
by Ootani et al (Date and Sato, 2015; Ootani et al., 2009). More recently, a long 
lasting mini-gut organoid culture was developed for mouse ISCs (Intestinal stem 
cells), wherein the culture can be derived from a single intestinal stem cell 
without mesenchymal fibroblasts or other cells (Date and Sato, 2015). The mini-
gut organoids culture is maintained in a mesenchymal-free environment 
comprising Matrigel and intestinal stem cell niche factors such as EGF, Wnt3a, 
Noggin and R-spondin. This mini-gut organoid recapitulates in vivo intestinal 
hierarchal organization and normal self-renewal and differentiation: single stem 
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cells initially form villus-like cystic structures and subsequently the cysts forms 
crypt-like budding structures.  Intestinal stem cells and Paneth cells reside at the 
tip of the budding structure and differentiating cells migrate toward the central 
cystic structure recapitulating the normal process of self-renewal and 
differentiation of intestinal stem cells and epithelial cells.  
 
1.5 Summary of dissertation 
In this dissertation, I describe in Chapter 2, mutual exclusivity between 
BRAF mutation an APC mutations in CRCs based on my analysis of The Cancer 
Genome Atlas(TCGA) CRC database and previously published data(Cancer 
Genome Atlas, 2012; Jorissen et al., 2015). Unlike KRAS mutations, BRAF 
mutations have a tendency towards being mutually exclusive with APC mutations 
in CRCs. As discussed earlier, the latter are the main drivers of Wnt activation in 
CRC . In Chapter 3, I show how BRAF mutations, in contrast to KRAS mutations, 
induce stem cell niche factor independent growth and tumorigenic 
transformation in mouse proximal colon organoids without engineering a 
concurrent APC mutation. This BRAF mutation induced single-step 
transformation starkly contrasts with previous studies showing requirement of 
multiple genetic hits, including APC disruption, for KRAS mutation to drive 
tumorigenesis (Drost et al., 2015). Upon induction, both BRAFV600E mutation and 
KRASG12D mutation promoted sphere formation which is the same phenotype as 
described in APC mutant organoids. Furthermore, only BRAFV600E mutant 
organoids gained independency in growth from having to add stem cell niche 
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factors such as EGF, Wnt3a, R-spondin and Noggin and tumorigenicity in 
Xenograft assays without any concurrent APC mutations. Molecular analysis 
revealed BRAFV600E mutant organoids autonomously activate Wnt signaling and 
stem cell signaling without external signaling from stem cell niche factors. 
Methylation analysis revealed the BRAFV600E organoids to have the CpG Island 
Methylator Phenotype (CIMP) with the genes affected by increased DNA 
methylation in promoter CpG islands including multiple Wnt negative regulator 
genes and genes that would normally cause senescence and blunt stem cell 
activity, and that would normally induce and maintain differentiation. These 
findings strongly suggest that the abnormal methylation plays an important role 
in the autonomous activation of Wnt and stem cell signaling pathways. Finally, b-
catenin mutations were observed in two of the  BRAFV600E mutant organoids 
indicating that BRAFV600E activation can lead to selection for genetic changes 
which foster Wnt-independency and cooperate with the epigenetic alterations.   
 





CHAPTER 1. INTRODUCTION 
 
	 14	
Figure 1.1 Molecular subtypes of CRCs 
(CIMP: CpG Island Methylator Phenotype, MSI: Microsatellite Instability, MSS: 
Microsatellite Stable, CIN: Chromosomal Instability) 
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Figure 1.2 Summary of Wnt pathways and the cellular hierarchy and 
stem cell niche factors in colon crypts and colon organoids 
(A) Red shade represents Wnt activation by Wnt ligands. As Wnt ligands bind to 
their receptor, Frizzled and LRP5/6, their cytosolic domains induce dissociation 
of β-catenin destruction complexes by sequestering their key components such as 
DVL, GSK3β, and AXIN. Therefore, β-catenins are protected from 
phosphorylation by GSK3β and subsequent degradation by uniquitin-proteasome 
pathway. Eventually, non-phosphorylated β-catenins are translocated to nucleus 
and activate its target gene expression in corporation with TCF. Purple shade 
represents a situation where Wnt ligand is not present or the Wnt pathway is 
negatively regulated by Wnt negative regulators. When Wnt ligands are not 
present, β-catenin destruction complex sequestrate β-catenins and subsequently 
induce their degradation through ubiquitin-protease pathway. The lack of β-
catenin in the nucleus let TLE bind to TCF and suppress expression of Wnt target 
genes. There are several Wnt negative regulators. SFRP inhibits at the level of 
Wnt ligands through direct binding and sequestration of them. On the other 
hands, DKK binds to Wnt ligand receptor, LRP5/6 and Frizzled proteins and, 
therefore, inhibit their interaction with Wnt ligands. WT1 induces expression of 
WID, which is antagonist of Dvl. Sox17 is an antagonist of TCF though direct 
binding. (B) Colon crypt is consist of intestinal stem cells (ISC), Paneth cells, +4 
cells, and differentiated enterocytes. The self-renewing ISCs reside at the bottom 
of the crypt and their progenies migrate upward along the crypt. The 
maintenance of this cellular hierarchy is highly regulated by the stem cell niche 
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factors such as Wnt3a, RSPO and Noggin and differentiation factors BMP. Colon 
organiod maintains the same cellular hierarchy. The ISC reside at the tip of 
budding structures that grow out from the central cystic structure. The 
differentiating enterocyte migrates toward the central cystic structure.  
 




Chapter 2: Mutual exclusivity between BRAF and APC 
mutations in colorectal cancers  
 
2.1 Introduction 
APC mutations are regarded as the main driver genetic alterations in CRCs. 
In fact, these are one of the earliest events in many CRCs and one of the most 
prevalent mutations in these cancers  (Jorissen et al., 2015). The majority of APC 
mutations are frameshift or nonsense mutations, which results in the loss of APC 
function, disruption of the destruction complex for beta catenin leading to 
accumulation of this protein and Wnt activation(Fearon, 2011). In the tumors 
with APC mutations, aberrant Wnt activation is observed early on at the low-
grade adenoma stage and in the majority of the cells. Mouse models with APC 
mutations develop adenomas in the small and large intestine with 
hyperactivation of Wnt signaling (Fearon, 2011). Germline mutations of the APC 
gene also cause familial adenomatous polyposis (FAP) syndrome in humans 
which is characterized by increased incidence of polyp formation in the colon and 
increased predisposition to CRC development.  
BRAFV600E also has been considered as a driver mutation in a subtype of 
CRCs. The tumors with BRAFV600E tend to have a sessile serrated polyp as a 
precursor lesion (Ensari et al., 2010; Kambara et al., 2004; Makinen, 2007; 
Minoo et al., 2007; Snover, 2011; Vakiani and Yantiss, 2009; Yang et al., 2004), 
mucinous adenocarcinoma as a histopathological type (Ensari et al., 2010; 




Kambara et al., 2004; Makinen, 2007; Minoo et al., 2007; Snover, 2011; Vakiani 
and Yantiss, 2009; Yang et al., 2004) and have the CpG Island Methylator 
Phenotype(CIMP)-high and microsatellite instability as molecular features 
(Hinoue et al., 2009; Ogino et al., 2006). Despite having different 
histopathological and molecular features, BRAF mutant tumors also have 
increasing levels of Wnt activation as do the APC mutant tumors (Murakami et 
al., 2015). However, unlike for the more rapid increase of Wnt activation in APC 
mutant tumors, BRAF tumors undergo gradual increase of Wnt activity as they 
progress from low to high grade. The same gradual increase of Wnt activity is also 
observed in mouse intestinal tumors driven by BRAF mutation (Rad et al., 2013). 
In addition, the increase of Wnt activity is associated with increase of DNA 
methylation in promoter regions of Wnt negative regulators such as AXIN2, 
SFRP1, SFRP2, and SFRP4 but not with loss of APC expression. It is proposed 
that epigenetic silencing of these Wnt negative regulators could be the main 
driver of Wnt activation in the BRAF mutant tumors rather than APC mutations 
(Lee et al., 2008; Nosho et al., 2008; Suva et al., 2013; Toyota et al., 1999). There 
are only a few studies formally investigating these above relationships between 
APC and BRAF mutations although it is widely accepted that KRAS and APC 
mutations co-occur in vast majority of CRCs. In this chapter, I will discuss the 
relationships between APC and BRAF mutations and the unique molecular 
features of BRAF mutant tumors based on data from The Cancer Genome Atlas 
(TCGA) database and an Australian cohort database.  






2.2.1 APC and BRAF mutations have a tendency to be mutually 
exclusive in an Australian CRC cohort 
A recent study of an Australian CRC patient cohort included the mutation 
status of 746 colorectal tumors (Jorissen et al., 2015). Using the data, we 
examined the relationships between major driver mutations including BRAF, 
KRAS and APC in the above CRCs. Among 746 tumors, 67 have BRAF mutations 
and only 14 of the 67 tumors have APC mutations at the same time. The Fisher’s 
exact test revealed a strong tendency toward mutual exclusivity with Odds Ratio 
(OR) of 0.09782335 and p-value less than 2.2e-16 (Figure 2.1A) (Gao et al., 2013). 
Among the same cohort, 262 tumors harbor KRAS mutations and 211 out of 262 
tumors have concurrent APC mutations.  Fisher’s test showed a tendency toward 
co-occurrence with OR of 2.556757 and p-value of 1.096e-07 (Gao et al., 2013).  
 
2.2.2. APC and BRAF mutations also have a tendency to be mutually 
exclusive in the TCGA CRC cohort 
   Mutational status of APC, KRAS and BRAF, CIMP status, microsatellite 
instability(MSI) status, hyerpmutator phenotype, anatomic location and 
histopathological type of CRCs in the TCGA cohort were retrieved from the TCGA 
data(Table 2.1) (Cancer Genome Atlas, 2012). As previously reported (Guinney et 
al., 2015; Hinoue et al., 2009; Hughes et al., 2012; Jass, 2007; Lee et al., 2008; Li 




and Lai, 2009; Makinen, 2007; Morkel et al., 2015; Nosho et al., 2008; O'Brien et 
al., 2006; Ogino et al., 2006; Treanor and Quirke, 2007; Vakiani and Yantiss, 
2009; Weisenberger et al., 2006; Yamamoto et al., 2012), BRAF mutant tumors 
are associated with CIMP-H and MSI-H and KRAS tumors with CIMP-L and 
MSS (Figure 2.2) consistent with data from other cohorts.  
Among 224 tumors, 21 have BRAF mutations and only 8 of the 21 tumors 
have APC mutations at the same time. The Fisher’s exact test revealed some 
tendency toward mutual exclusivity with OR of 0.1388884 and p-value less than 
4.25e-05 (Figure 2.3A) (Gao et al., 2013). Among the same cohort, 94 tumors 
harbor KRAS mutations and 80 out of 94 tumors have concurrent APC mutations.  
Fisher’s test showed a tendency toward co-occurrence with OR of 2.181095 and 
p-value of 2.3e-02 (Gao et al., 2013).  
In addition, BRAF mutant tumors in this cohort tend to have less 
homozygous APC loss (2 out of 8 tumors), which accounts for more than half of 
the APC mutations in KRAS mutant tumors (40 out of 77 tumors) and tumors 
without mutations in BRAF and KRAS (51 out of 85 tumors) (Table 2.1 and 
Figure 2.4). Pearson Chi square test revealed that BRAF mutant tumors positively 
associate with wild type APC and negatively associate with homozygous APC loss.  
 
2.3 Discussion 
As discussed in chapter one, among CRC, there are different disease 
entities rather than one(Guinney et al., 2015; Hughes et al., 2012; Jass, 2007; Lee 




et al., 2008; Li and Lai, 2009; Makinen, 2007; Morkel et al., 2015; Nosho et al., 
2008; O'Brien et al., 2006; Ogino et al., 2006; Treanor and Quirke, 2007; 
Vakiani and Yantiss, 2009; Weisenberger et al., 2006; Yamamoto et al., 2012). 
Among those groups, Group 1 and 2 have a tendency to have mutations in BRAF 
not in APC (Figure 1.1). It has been proposed that in these latter tumors 
epigenetic modulation of the Wnt pathway replaces the role of APC mutations. 
However, the exact process has not been modeled and yet proven. Even the 
relationships between BRAF mutations and APC mutations has not been well 
studied. In this chapter, the association studies with the Australian and TCGA 
CRC cohorts revealed a negative correlation between BRAF and APC. Although 
there is difference in the strength of tendency and significance, both cohorts 
suggest a mutual exclusivity implicating BRAF mutations may not require 
concurrent APC mutations to initiate and drive progression of CRCs in contrast 
to CRCs with KRAS mutations, which appear to require Wnt-activation by APC 
mutations for progression. How BRAF mutations drive tumorigenesis without a 
preceding requirement for Wnt-activation by APC mutations will be discussed in 
detail in Chapter 3 with new evidence discovered through modeling of the BRAF 
mutant CRCs in organoid culture.  
 
2.4 Material and Methods 
2.4.1 Analysis of TCGA CRCs 




Mutation, CIMP phenotype, MSI status, MLH1 methylation, hypermutator 
phenotype, anatomic location, histopathologic type and patient’s gender were 
acquired from supplementary data from a previously published article (Cancer 
Genome Atlas, 2012). The associations were evaluated by Fisher’s exact test or 
Chi square test. 
 
2.4.2 Analysis of Australian CRCs 
The mutational information of CRC in the Australian cohort was acquired 
from a previously reported article (Jorissen et al., 2015). The associations were 
evaluated by Fisher’s exact test or Chi square test.  





Patient APC1 APC2 BRAF KRAS CIMP MLH1 MSI HM Location Type Gender
TCGA-AG-A002 R1432X E1518X F247L Cluster3 - MSS HM rectum ADC M
TCGA-AA-A00D R546X R1432X V600E CIMP-H - MSS nHM Rt colon ADC M
TCGA-AA-3715 A1089V V600E G12D CIMP-H Me MSI-H HM Rt colon ADC M
TCGA-AA-3947 E829fs V600E CIMP-H Me MSI-H HM Rt colon Muc F
TCGA-AA-A00J R536X V600E CIMP-H Me MSI-H HM Rt colon Muc M
TCGA-AA-A01D deletion V600E CIMP-L - MSS nHM Lf colon Muc F
TCGA-AA-3684 E966X V600E CIMP-L - MSS nHM Rt colon Muc F
TCGA-AG-3578 deletion V600E Cluster3 - MSS nHM rectum Muc F
TCGA-AA-3664 V600E CIMP-H - MSS nHM Rt colon ADC F
TCGA-AA-3833 V600E CIMP-H Me MSI-H HM Rt colon ADC F
TCGA-AA-A01P V600E CIMP-H Me MSI-H HM Rt colon ADC F
TCGA-AA-A022 V600E CIMP-H Me MSI-H HM Rt colon ADC F
TCGA-AA-3525 V600E CIMP-H Me MSI-H HM Rt colon ADC M
TCGA-A6-2676 V600E CIMP-H Me MSI-H HM Rt colon Muc F
TCGA-AA-3516 V600E CIMP-H Me MSI-H HM Rt colon Muc F
TCGA-AA-3821 V600E CIMP-H Me MSI-H HM Rt colon Muc F
TCGA-AA-3949 V600E CIMP-H Me MSI-H HM Rt colon Muc F
TCGA-AA-3543 V600E CIMP-H Me MSI-H HM Rt colon Muc M
TCGA-A6-2672 V600E CIMP-H Me MSI-H HM Tr colon ADC F
TCGA-AA-3877 V600E CIMP-H Me MSI-H HM Tr colon Muc F
TCGA-AA-3966 V600E CIMP-L Me MSI-H HM Rt colon Muc F
TCGA-AA-A00A E1560fs V291fs G12D CIMP-H - MSI-H HM Rt colon ADC M
TCGA-AG-A02X E1291X deletion Q61L CIMP-H - MSS nHM rectum ADC M
TCGA-AA-A03F R787X R1432X G12D CIMP-H - MSS nHM Rt colon Muc F
TCGA-AA-3837 Q1276X E190fs G12V CIMP-H - MSS nHM Rt colon Muc M
TCGA-AA-3994 R787X T1469fs G12D CIMP-H - MSS nHM Tr colon Muc M
TCGA-AA-A01R R858X R1432X G13D CIMP-L - MSI-H HM Rt colon Muc M
TCGA-AA-3680 S1145fs E1555fs G13D CIMP-L - MSI-L nHM Rt colon ADC F
TCGA-AA-3930 R1432X S945fs G12D CIMP-L - MSI-L nHM Rt colon ADC M
TCGA-AA-3555 R499X R1450X A146T CIMP-L - MSS HM Rt colon Muc F
TCGA-AA-3848 R216X deletion G12D CIMP-L - MSS nHM Lf colon ADC F
TCGA-AA-3558 R554X Q1378X G12V CIMP-L - MSS nHM Lf colon ADC M
TCGA-AG-3599 C507X R1432X G12D CIMP-L - MSS nHM rectum NA M
TCGA-AA-3681 R906X R1432X A146T CIMP-L - MSS nHM Rt colon ADC F
TCGA-AA-3695 R223X deletion G12D CIMP-L - MSS nHM Rt colon ADC F
TCGA-AA-3818 S1393fs S960fs G12D CIMP-L - MSS nHM Rt colon ADC F
TCGA-AA-3522 C1392X deletion G12C CIMP-L - MSS nHM Rt colon ADC M
TCGA-AA-3864 R330X R1432X G12D Cluster3 - MSI-H HM Rt colon ADC M
TCGA-AA-3977 R1096X E1291X K117N Cluster3 - MSS HM Lf colon ADC M
TCGA-AA-A01K R858X Q1411X G12V Cluster3 - MSS nHM Lf colon ADC F
TCGA-AA-3521 L1471X deletion Q61L Cluster3 - MSS nHM Lf colon ADC M
TCGA-AG-3909 V812fs 1275fs A146T Cluster3 - MSS nHM rectum ADC F
TCGA-AG-3999 E200X deletion G12S Cluster3 - MSS nHM rectum ADC F
TCGA-AG-3726 Q649X S1264X G12V Cluster3 - MSS nHM rectum ADC F
TCGA-AG-A00C E1191X E1379X G12V Cluster3 - MSS nHM rectum ADC F
TCGA-AG-3611 G549X deletion A146V Cluster3 - MSS nHM rectum ADC M
TCGA-AG-4005 S1180X Q1310X G12V Cluster3 - MSS nHM rectum ADC M
TCGA-AG-3586 S752X Y938C G12V Cluster3 - MSS nHM rectum NA F
TCGA-AA-3851 R1432X deletion G12D Cluster3 - MSS nHM Rt colon ADC M
TCGA-AA-3939 Q524X R1432X G12D Cluster3 - MSS nHM Rt colon ADC M
TCGA-AA-3986 deletion deletion A146T Cluster3 - MSS nHM Tr colon ADC M
TCGA-AA-A00N S1263X E1390X G13D Cluster4 - MSI-L HM Rt colon Muc M
TCGA-AA-A02W R858X/E1356X deletion G12C Cluster4 - MSI-L nHM Lf colon ADC F
TCGA-AG-3892 R1096X N1143K E98X Cluster4 - MSS HM rectum ADC F
TCGA-AA-3975 R481X E1288X K68N Cluster4 - MSS nHM Lf colon ADC M
TCGA-AG-A032 R284X E1304X G12C Cluster4 - MSS nHM rectum ADC M
TCGA-AG-3887 Q1242X 1291fs G12D Cluster4 - MSS nHM rectum Muc M




Table 2.1 (Continued) 
Patient APC1 APC2 BRAF KRAS CIMP MLH1 MSI HM Location Type Gender
TCGA-AA-3530 Q1451X deletion G12V Cluster4 - MSS nHM Rt colon ADC M
TCGA-AG-A02N R232X R1432X A146T NA NA MSI-H HM rectum ADC M
TCGA-AG-A01W R858X deletion G13D NA NA MSS nHM rectum ADC F
TCGA-AG-A020 R1432X Q1244fs G12V NA NA MSS nHM rectum Muc F
TCGA-AA-A029 Y935fs G12V CIMP-H - MSI-L nHM Rt colon ADC M
TCGA-AA-A02O T1283fs G12D CIMP-H - MSS nHM Tr colon ADC M
TCGA-AA-3870 R858X G12D CIMP-H Me MSS nHM Rt colon ADC F
TCGA-AA-3854 S1380fs G12V CIMP-L - MSI-L nHM Lf colon Muc F
TCGA-A6-2683 deletion G12V CIMP-L - MSI-L nHM Rt colon ADC M
TCGA-AA-3852 S1403fs G12A CIMP-L - MSI-L nHM Tr colon Muc M
TCGA-AA-A00Q deletion G12D CIMP-L - MSS nHM Lf colon ADC F
TCGA-AA-3979 Q739X A146T CIMP-L - MSS nHM Lf colon ADC M
TCGA-AA-A01I Y917X G12V CIMP-L - MSS nHM Lf colon ADC M
TCGA-AA-3556 Y917X G12R CIMP-L - MSS nHM Lf colon NA M
TCGA-AF-2691 S1328X G12D CIMP-L - MSS nHM rectum ADC F
TCGA-AG-3605 Q1360X G13D CIMP-L - MSS nHM rectum ADC F
TCGA-AG-3878 S578X G12D CIMP-L - MSS nHM rectum ADC M
TCGA-AG-3902 G1270X G13D CIMP-L - MSS nHM rectum ADC M
TCGA-AA-A01Z P1453fs G12D CIMP-L - MSS nHM Rt colon ADC M
TCGA-AA-3673 K975X G12D CIMP-L - MSS nHM Tr colon ADC F
TCGA-AA-A00K Q1349X G12V Cluster3 - MSI-L nHM Lf colon ADC M
TCGA-AA-A01F R827H G12V Cluster3 - MSS nHM Lf colon ADC M
TCGA-AG-3896 R858X G12C Cluster3 - MSS nHM rectum ADC F
TCGA-AG-3602 S1328X G12D Cluster3 - MSS nHM rectum ADC F
TCGA-AG-A015 E1268X G12D Cluster3 - MSS nHM rectum ADC F
TCGA-AG-3727 E1277X G13D Cluster3 - MSS nHM rectum ADC F
TCGA-AG-A025 Q1360fs Q22K Cluster3 - MSS nHM rectum ADC F
TCGA-AG-3580 E1239X G12D Cluster3 - MSS nHM rectum ADC M
TCGA-AG-4008 deletion G12L Cluster3 - MSS nHM rectum ADC M
TCGA-AG-3581 R546X G13D Cluster3 - MSS nHM rectum ADC M
TCGA-AG-3901 M1413fs A146T Cluster3 - MSS nHM rectum Muc F
TCGA-AG-3594 1219fs G12V Cluster3 - MSS nHM rectum Muc M
TCGA-AA-3548 R787X G12D Cluster3 - MSS nHM Rt colon ADC F
TCGA-AA-3814 E1390X G12S Cluster3 - MSS nHM Rt colon ADC F
TCGA-AA-3561 R858X G12D Cluster3 - MSS nHM Rt colon ADC M
TCGA-AG-3583 Q173X G12D Cluster4 - MSI-L nHM rectum Muc M
TCGA-AA-3696 S1385fs G12C Cluster4 - MSS nHM Lf colon ADC F
TCGA-AA-3532 Q636X G12D Cluster4 - MSS nHM Lf colon ADC M
TCGA-AG-A014 E1191X G12S Cluster4 - MSS nHM rectum ADC M
TCGA-AG-A008 K1067X G12V Cluster4 - MSS nHM rectum Muc F
TCGA-AF-2692 S695X G12V Cluster4 - MSS nHM rectum NA F
TCGA-AG-3575 G12V CIMP-H - MSS nHM rectum ADC M
TCGA-AA-3845 Q61K CIMP-H Me MSI-H HM Rt colon NA F
TCGA-AA-3672 Q61K CIMP-H Me MSI-H HM Tr colon ADC F
TCGA-AA-A01G K117N CIMP-L - MSI-L nHM Rt colon Muc M
TCGA-AA-A03J G12C CIMP-L - MSS nHM Lf colon ADC F
TCGA-AA-3842 G13D CIMP-L - MSS nHM Lf colon ADC M
TCGA-AF-2689 G13D CIMP-L - MSS nHM rectum ADC F
TCGA-AA-A02Y G12V CIMP-L - MSS nHM Rt colon ADC M
TCGA-AA-3520 G12V Cluster3 - MSI-L nHM Rt colon ADC F
TCGA-AA-3560 G12D Cluster3 - MSS nHM Lf colon ADC F
TCGA-AA-A01X G12V Cluster3 - MSS nHM Lf colon ADC F
TCGA-AG-A00H A146T Cluster4 - MSS nHM rectum ADC M
TCGA-AA-3710 A209V I1236N CIMP-H Me MSI-H HM Rt colon ADC F
TCGA-AA-A01Q R546X I2497V CIMP-L - MSI-H HM Rt colon ADC F
TCGA-AG-4007 Q1285X E1361X CIMP-L - MSI-L nHM rectum ADC M
TCGA-AG-3598 R216X R232X CIMP-L - MSS nHM rectum ADC M




Table 2.1 (Continued) 
  
Patient APC1 APC2 BRAF KRAS CIMP MLH1 MSI HM Location Type Gender
TCGA-AG-A011 K652X Q1388X CIMP-L - MSS nHM rectum ADC M
TCGA-AG-3881 Q1349X deletion CIMP-L - MSS nHM rectum NA F
TCGA-AA-A01V R1432X S1401N CIMP-L - MSS nHM Rt colon ADC M
TCGA-AA-A00U R858X R1432X CIMP-L - MSS nHM Rt colon ADC M
TCGA-AA-3982 R284X R1432X Cluster3 - MSI-L nHM Lf colon ADC M
TCGA-AA-3866 Q1017X deletion Cluster3 - MSI-L nHM Rt colon ADC F
TCGA-AA-A02H H289fs deletion Cluster3 - MSS nHM Lf colon ADC F
TCGA-AA-3976 Q883X M1395fs Cluster3 - MSS nHM Lf colon ADC M
TCGA-A6-2670 E1353X deletion Cluster3 - MSS nHM Lf colon ADC M
TCGA-AA-3562 R481X deletion Cluster3 - MSS nHM Lf colon ADC M
TCGA-AA-3858 V1334fs deletion Cluster3 - MSS nHM Lf colon ADC M
TCGA-AA-3544 Q960X S1328X Cluster3 - MSS nHM Lf colon ADC M
TCGA-AG-A01L S836fs deletion Cluster3 - MSS nHM rectum ADC M
TCGA-AG-3890 T916fs deletion Cluster3 - MSS nHM rectum ADC M
TCGA-AG-3898 R787X/Q1023E deletion Cluster3 - MSS nHM rectum ADC M
TCGA-AG-A026 C1252X deletion Cluster3 - MSS nHM rectum ADC M
TCGA-AA-3519 R216X E1288X Cluster3 - MSS nHM rectum ADC M
TCGA-AA-3552 R1432X deletion Cluster3 - MSS nHM Rt colon ADC M
TCGA-AA-A010 R1432X A513V Cluster4 - MSI-L HM Tr colon ADC F
TCGA-AA-3553 S1297X deletion Cluster4 - MSI-L nHM Lf colon ADC F
TCGA-AA-A00O Q1349X deletion Cluster4 - MSI-L nHM Lf colon ADC F
TCGA-AA-3531 R232X Q1134X Cluster4 - MSI-L nHM Lf colon ADC F
TCGA-AA-3667 R546X S1382X Cluster4 - MSI-L nHM Lf colon ADC F
TCGA-AA-3973 R265X Q1360X Cluster4 - MSI-L nHM Lf colon ADC M
TCGA-AA-3688 E923X deletion Cluster4 - MSI-L nHM Lf colon ADC M
TCGA-AA-3692 R787X E1356X Cluster4 - MSI-L nHM Lf colon Muc F
TCGA-AG-3601 Q246X/S1297X deletion Cluster4 - MSI-L nHM rectum ADC M
TCGA-AA-3984 R1096X F2766C Cluster4 - MSS HM Lf colon ADC F
TCGA-AA-A02F L478fs G1312fs Cluster4 - MSS nHM Lf colon ADC F
TCGA-AA-3538 K921X deletion Cluster4 - MSS nHM Lf colon ADC F
TCGA-AA-3678 1293fs deletion Cluster4 - MSS nHM Lf colon ADC F
TCGA-AA-3812 S1403fs V539A Cluster4 - MSS nHM Lf colon ADC F
TCGA-AA-3860 L235X Q1320X Cluster4 - MSS nHM Lf colon ADC F
TCGA-AA-A02J R223X T1380fs Cluster4 - MSS nHM Lf colon ADC F
TCGA-AA-3542 E1356X deletion Cluster4 - MSS nHM Lf colon ADC M
TCGA-AA-3872 T1420fs deletion Cluster4 - MSS nHM Lf colon ADC M
TCGA-AA-3679 R216X 1289fs Cluster4 - MSS nHM Lf colon ADC M
TCGA-AA-3685 Q960X K1352X Cluster4 - MSS nHM Lf colon ADC M
TCGA-AG-3612 Q1388X deletion Cluster4 - MSS nHM rectum ADC F
TCGA-AG-3882 V579fs deletion Cluster4 - MSS nHM rectum ADC F
TCGA-AG-4015 Y1358X deletion Cluster4 - MSS nHM rectum ADC F
TCGA-AG-3609 Q1349X Y1165X Cluster4 - MSS nHM rectum ADC F
TCGA-AG-A02G R223X deletion Cluster4 - MSS nHM rectum ADC M
TCGA-AG-3587 R1096X E1288X Cluster4 - MSS nHM rectum ADC M
TCGA-AA-A01S Q394X R546X Cluster4 Me MSI-L nHM Lf colon ADC F
TCGA-AG-A01Y Q1276X deletion NA NA MSS nHM rectum ADC F
TCGA-AG-A036 R284X Q1388X NA NA MSS nHM rectum ADC M
TCGA-AA-3972 E829fs CIMP-L - MSI-L nHM Lf colon ADC M
TCGA-AA-3855 F1336fs CIMP-L - MSI-L nHM Lf colon ADC M
TCGA-AG-3584 R1432X CIMP-L - MSS nHM rectum ADC M
TCGA-AA-3527 Q1210X CIMP-L - MSS nHM Rt colon ADC F
TCGA-AA-3549 C1392S CIMP-L - MSS nHM Rt colon ADC M
TCGA-AA-3989 R216X CIMP-L - MSS nHM Tr colon ADC M
TCGA-AA-A00R R876X CIMP-L Me MSI-H HM Rt colon ADC F
TCGA-AA-A024 R387X Cluster3 - MSI-L nHM Lf colon Muc M
TCGA-AA-3846 Q1360X Cluster3 - MSS nHM Lf colon ADC F
TCGA-AA-A01T R1096X Cluster3 - MSS nHM Lf colon ADC F




Table 2.1 (Continued) 
Patient APC1 APC2 BRAF KRAS CIMP MLH1 MSI HM Location Type Gender
TCGA-AA-A00F deletion Cluster3 - MSS nHM Lf colon ADC M
TCGA-AA-A00W R858X Cluster3 - MSS nHM Lf colon ADC M
TCGA-AY-4071 R1417fs Cluster3 - MSS nHM NA NA F
TCGA-AG-3593 E1335X Cluster3 - MSS nHM rectum ADC F
TCGA-AG-3894 R216X Cluster3 - MSS nHM rectum ADC M
TCGA-AG-3883 R265X Cluster3 - MSS nHM rectum ADC M
TCGA-A6-2677 Q462X Cluster3 - MSS nHM Rt colon ADC F
TCGA-AA-A00L R1096X Cluster3 - MSS nHM Tr colon ADC M
TCGA-AA-3554 A2028T Cluster4 - MSI-H HM Rt colon ADC F
TCGA-AA-3529 V291fs Cluster4 - MSI-L nHM Lf colon ADC F
TCGA-AG-4001 R858X Cluster4 - MSI-L nHM rectum ADC F
TCGA-A6-3807 R223X Cluster4 - MSS nHM Lf colon ADC F
TCGA-AA-3693 E1277fs Cluster4 - MSS nHM Lf colon ADC F
TCGA-AA-A017 Q1226X Cluster4 - MSS nHM Lf colon ADC F
TCGA-AA-3524 Q215ss Cluster4 - MSS nHM Lf colon ADC M
TCGA-AA-3856 R858X Cluster4 - MSS nHM Lf colon ADC M
TCGA-AA-3952 R223X Cluster4 - MSS nHM Lf colon ADC M
TCGA-AA-3955 M1383fs Cluster4 - MSS nHM Lf colon ADC M
TCGA-AA-A00Z R216X Cluster4 - MSS nHM Lf colon ADC M
TCGA-A6-2674 R536X Cluster4 - MSS nHM Lf colon Muc M
TCGA-AF-3913 P1301fs Cluster4 - MSS nHM rectum ADC M
TCGA-AG-3893 S1338X Cluster4 - MSS nHM rectum ADC M
TCGA-AF-3400 Q1276X Cluster4 - MSS nHM rectum Muc M
TCGA-AA-3666 F1336fs Cluster4 - MSS nHM Rt colon ADC M
TCGA-AG-3600 CIMP-H - MSS nHM rectum ADC M
TCGA-AA-3518 CIMP-H Me MSI-H HM Rt colon ADC F
TCGA-AA-A00E CIMP-H Me MSI-H HM Rt colon ADC M
TCGA-AA-A004 CIMP-L - MSI-L nHM Lf colon ADC M
TCGA-AA-3831 CIMP-L - MSS nHM Lf colon ADC M
TCGA-AG-3608 CIMP-L - NA nHM rectum ADC F
TCGA-AA-3819 Cluster3 - MSI-L nHM Lf colon ADC F
TCGA-AA-3526 Cluster3 - MSI-L nHM Lf colon ADC M
TCGA-AG-3574 Cluster3 - MSS nHM rectum ADC F
TCGA-AG-A016 Cluster3 - MSS nHM rectum ADC M
TCGA-AA-3514 Cluster3 - MSS nHM Rt colon ADC F
TCGA-AA-3534 Cluster3 - MSS nHM Rt colon ADC F
TCGA-AA-3875 Cluster3 - MSS nHM Rt colon ADC F
TCGA-AY-4070 Cluster3 - MSS nHM Rt colon ADC F
TCGA-AA-3956 Cluster3 - MSS nHM Rt colon ADC M
TCGA-A6-2678 Cluster3 - MSS nHM Tr colon ADC F
TCGA-AA-3517 Cluster4 - MSI-L nHM Lf colon ADC M
TCGA-AA-3971 Cluster4 - MSS nHM Lf colon ADC M
TCGA-AG-3582 Cluster4 - MSS nHM rectum ADC M
TCGA-AA-3869 Cluster4 - MSS nHM Rt colon ADC M
TCGA-AA-3941 H1472fs NA G12D CIMP-H - MSI-L nHM Rt colon ADC F
TCGA-A6-3808 R787X NA G12D Cluster3 - MSI-L nHM Rt colon Muc M
TCGA-AA-3844 NA G12V Cluster3 - MSS nHM Lf colon ADC F
TCGA-AG-A00Y NA G12D Cluster3 - MSS nHM rectum ADC M
TCGA-AA-3980 R232X NA Cluster3 - MSS nHM Lf colon ADC F
TCGA-A6-3810 I1286fs NA Cluster4 - MSS nHM Lf colon ADC M
TCGA-AA-3850 NA CIMP-L - MSS nHM Tr colon ADC M
TCGA-AA-3867 NA Cluster4 - MSS nHM Lf colon ADC M
TCGA-AA-3811 NA Cluster4 Me MSI-H HM Rt colon ADC F




Table 2.1 Summary of TCGA CRC data for APC, BRAF and KRAS 
mutations, CpG Island Methylator Phenotype, Microsatellite 
Instability, anatomic location and histopathology type 
Blue color represents APC mutation status. Darkest blue means deletion, lighter 
blue for frame shift, non-sense or point mutation. Orange and brown stand for 
BRAF and KRAS mutations respectively.  (Me : methylation, HM: hypermutator, 
nHM: non-hypermutator, Rt: right, Lf: left, ADC: adenocarcinoma, Muc: 
mucinous adenocarcinoma, M: male, F: female) 









Figure 2.1 BRAF and APC mutations in 746 CRCs in the Australian 
cohort have a strong tendency toward mutual exclusivity 
(A) Fisher’s exact test for an exclusivity / co-occurrence between BRAF and APC. 
p-value is lower than 2.2e-16 and odds ratio is 0.09782335. Based on cBioPortal’s 
odds ratio interpretation, there is a strong tendency toward mutual exclusivity 
between BRAF and APC mutations in this cohort. (B) Fisher’s exact test for an 
exclusivity / co-occurrence between KRAS and APC. p-value is 1.096e-07 and 
odds ratio is 2.556757. Based on cBioPortal’s odds ratio interpretation, there is a 
tendency toward co-occurence between KRAS and APC mutations in this cohort. 
(C) Interpretation criteria for odds ratio in cBioPortal (Gao et al., 2013). 









Figure 2.2 Molecular features of 224 CRC in the TCGA cohort 
correlate with previous reports on these cancers  
(A) Mosaic plot and Pearson Chi square for molecular features such as BRAF 
mutation, CpG Island Methylator Phenotype(CIMP) status and Microsatellite 
Instability(MSI). As previously reported BRAF mutant tumors have a strong 
association with CIMP-H and MSI-H phenotype and KRAS mutant tumors are 
associated with CIMP-L and MSS phenotype indicating the cohort represents a 
good spectrum for CRC samples collected.  









Figure 2.3 BRAF and APC mutations in 224 TCGA CRCs cohorts have 
some tendency toward mutual exclusivity 
(A) Fisher’s exact test for an exclusivity / co-occurrence between BRAF and APC 
mutations. p-value is 4.25e-05 and odds ratio is 0.1388884. Based on 
cBioPortal’s odds ratio interpretation, there is some tendency toward mutual 
exclusivity between BRAF and APC mutations in this cohort. (B) Fisher’s exact 
test for an exclusivity / co-occurrence between KRAS and APC mutations. p-value 
is 2.393e-02 and odds ratio is 2.181095. Based on cBioPortal’s odds ratio 
interpretation, there is a tendency toward co-occurence between KRAS and APC 
mutations in this cohort. (C) Interpretation criteria for odds ratio in cBioPortal 
(Gao et al., 2013). 










Figure 2.4 BRAF mutant CRC in the TCGA cohort are positively 
associated with wild type APC and negatively with homozygous APC 
loss. 
(A) Mosaic plot and Pearson Chi square test result. BRAF mutant tumors are 
positively associated with wild type APC and negatively with homozygous APC 
loss. In contrast, KRAS mutant tumor and tumors without mutations in KRAS 
and BRAF are positively associated with homozygous APC loss. (B) Bar graph for 
Standardized Pearson residual.  
CHAPTER 3. SINGLE-STEP INDUCTION OF RIGHT-SIDED COLON CANCER 
PHENOTYPE BY BRAFV600E THROUGH ACQUIRED WNT ACTIVATION 
 
	 37	
Chapter 3: Single-step induction of right-side colon cancer 
phenotype by BRAFV600E through acquired Wnt activation  
 
3.1. Introduction                              
A major question in cancer biology is how distinct cancer phenotypes 
evolve within the same organ system. In this regard, sporadic colorectal 
adenocarcinomas (CRC) differ in their phenotypes between right and left sided 
tumors (Ensari et al., 2010; Jass, 2007; Jorissen et al., 2015; Li and Lai, 2009; 
Pai et al., 2012).  While both types of tumors evolve as progression from benign 
adenomas to carcinomas, their molecular and pathological features are distinct 
from one another. It is much more common that left-sided CRCs have 
chromosomal instability (CIN), much less mutational burden, particularly with 
regards to not manifesting mismatch repair deficiencies (microsatellite stable, 
MSS) and less DNA methylation in promoter CpG island classified as non-CpG 
island methylator phenotype (CIMP-N) (Ensari et al., 2010; Jass, 2007; Jorissen 
et al., 2015; Pai et al., 2012; Weisenberger et al., 2006). Pathologically, the left-
sided CRCs arise from conventional adenomas such as tubular or villous 
adenomas (Li and Burgart, 2007).  On the contrary, right-sided CRCs have a 
tendency to have no CIN phenotype, higher mutational burden with regard to 
mismatch repair deficiencies (microsatellite instable, MSI) due to epigenetic 
silencing of MLH1 gene and much more prevalent CpG island DNA methylation 
classified as CIMP-H/L(Fearon, 2011; Jass, 2007; Li and Lai, 2009; Toyota et al., 
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1999; Weisenberger et al., 2006). In terms of pathological features, the right-
sided tumors originate from serrated polyps such as sessile serrated adenoma 
(SSA) or traditional serrated adenoma (TSA) and tend to develop mucinous 
adenocarcinomas (Li and Burgart, 2007). Different genetic mutational 
landscapes exist for the above tumors (Rad et al., 2013; Sugai et al., 2006; 
Yamamoto et al., 2012). The left sided tumors mostly have inactivating mutations 
or deletions of APC, leading to overactivity for Wnt signaling and have frequent 
activating KRAS mutations, 18q loss and inactivating p53 mutations (Fearon, 
2011). In contrast, the right-sided tumors frequently have activating BRAF 
mutations, mostly BRAFV600E mutation and less frequent inactivating mutations 
or deletions of APC as discussed in Chapter 2 (Fearon, 2011; Toyota et al., 1999; 
Weisenberger et al., 2006; Yamamoto et al., 2012).  
It is well accepted that early Wnt activation by APC mutations, plus the co-
ocurring early KRAS mutations provide the prime driving events for evolution of 
left-sided CRCs (Murakami et al., 2015). Importantly, recent mouse models 
suggest that the KRAS mutations provide their role virtually always in the context 
of co-occuring inactivating mutations of APC, p53 and SMAD4 (Drost et al., 2015; 
Matano et al., 2015). Mouse models for BRAF mutations, in contrast, suggest that 
these alone lead to small intestinal (Carragher et al., 2010) and colon carcinomas 
(Rad et al., 2013), but the mechanisms are much less clear than for the above 
events for the left-sided lesions. Precisely how the Wnt pathway is involved, and 
how CIMP arises is not known and the latter abnormality could be a key event 
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since among the genes that are abnormally silenced in the association with CIMP 
are those that have a normal role in suppressing Wnt signaling such as SFRP1 
and SFRP2 (Baylin and Ohm, 2006; Hinoue et al., 2009; Suzuki et al., 2004).  
The recent development of three dimensional (3D) intestinal organoids 
culture has made it possible to recapitulate the in vivo intestinal epithelial 
structure in vitro. These organoids consist of villus-like cystic structure and 
crypt-like structures budding outward (Date and Sato, 2015). Similar to the 
cellular hierarchy in vivo, the intestinal stem cells and Paneth cells locate at the 
bottom of the crypt-like budding structures, whereas differentiating epithelial 
cells migrate to the central cystic structure (Date and Sato, 2015; Sato et al., 2011). 
In addition, the organoids recapitulate a normal process of continual cell 
turnover: stem cells in the budding structure continue to divide and the 
progenitors differentiate while migrating to the central cyst structure and 
undergo apoptosis as they reach terminal differentiation. Therefore, the 
organoids can be maintained indefinitely without artificial immortalization 
process (Date and Sato, 2015; Sato et al., 2011).  
To enhance understanding of the functional implications of BRAF and 
KRAS mutations in the evolution of the distinct molecular and pathological 
phenotypes of CRC including epigenomic landscape, we developed a 3D organoid 
culture model harboring inducible BRAFV600E or KRASG12D mutations and closely 
investigated early changes in cellular behavior and molecular profiles including 
DNA methylation and gene expression.  
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3.2.1 Generation of proximal colon organoids with inducible 
mutations of BRAFV600E or KRASG12D 
To investigate the functional implication of KRASG12D and BRAFV600E in 
colon tumorigenesis, Cre-inducible BRAFV600E, KRASG12D and wild type colon 
organoid lines were established from mice heterozygous for BRAFV600E (termed 
BRAF+/LSL) or heterozygous for KRASG12D (termed KRAS+/LSL) or wild type for 
both proteins (WT) respectively (Figure 3.1, A and B). Both BRAF+/LSL and 
KRAS+/LSL organoids carry the corresponding targeted insertion of a mutant exon 
preceded by loxp flanked STOP cassette with polyadenylation sequence. Thus, the 
alleles do not express the mutant genes until Cre-mediated recombination of the 
loxp sites is instituted (Dankort et al., 2007; Jackson et al., 2001). In addition, 
both mouse strains were bred to carry Cre-inducible tdTomato which is used as 
surrogate marker for Cre-mediated recombination (Figure 3.1, C and D). The 
organoids were isolated from proximal 2.5 cm of mouse colon (Figure 3.1E).  
Cre-mediated activation of the oncogenes (BRAFCA, KRASCA) was achieved 
by lentiviral delivery of constitutively expressed Cre with a hygromycin selection 
marker (Figure 3.1F), while infection with lentivirus encoding only the selection 
marker served as a control (EV) (Figure 3.1F). Before Cre-mediated induction, 
the BRAF+/LSL and KRAS+/LSL organoids, identically to wild type (WT) organoids 
express only wild type BRAF and KRAS proteins, and are thus identical to the 
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wild type organoids. After expression of Cre, the BRAFCA and KRASCA organoids 
express one copy of the wild-type protein and one copy of the respective mutant 
protein, along with tdTomato, while the WT organoids express only tdTomato 
(Figure 3.1D).   
 
3.2.2 BRAFV600E and to a lesser extent, KRASG12D induce spheroid 
formation and inward polypoid growth  
Immediately after Cre expression and hygromycin-selection, both the 
BRAFCA and KRASCA organoids grow as cystic spheroid with a smooth periphery 
and clear lumen (Figure 3.2, C and D). The WT and EV control organoids 
(BRAFEV) have the typical structures previously defined with stem cell containing, 
intestinal crypt-like structures as buds on the outer surface of the central cystic 
structures, more mature intestinal cells in the central cystic structure, and a 
lumen-like structure with many dying mature cells modeling the course of 
generation and cell death that rapidly occurs in the intestine (Figure 3.2, A and B) 
(Date and Sato, 2015; Onuma et al., 2013).  Within 11 weeks, a high frequency of 
spheroid structures is observed for each expressed mutation (88.5% for BRAFCA 
and 84.7% for KRASCA) (Figure 3.2E).  
Despite that induction of both KRAS and BRAF mutations produced the 
above spheroidal growth of the organoids, important characteristics of the latter 
emerged which suggested more evolution towards having neoplastic properties. 
While WT and BRAFEV organoids in culture and in H&E staining show the typical 
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crypt-like buddings growing outwards (Figure 3.3, A and B) (Date and Sato, 
2015), these structures grow inwards for the BRAF mutant organoids (BRAFCA) 
indicating polypoid growth with dysplastic changes (Figure 3.3, C and D). Similar 
polypoid growth has been reported in APC knock out mutant organoids (Li et al., 
2014). The cells in the BRAFCA organoids also show other dysplastic changes such 
as high nuclear to cytoplasm ratio and atypical columnar changes (Figure 3.3C). 
The KRASCA organoids much less frequently show the polypoid growth into the 
lumen (Figure 3.3E), and for the most part grow as cystic structures with a clear 
lumen (Figure 3.3F). The above spheroidal structures are characteristic of CRC 
organoids with introduced APC mutations, which drive, in primary CRC and in 
the organoids, oncogenic Wnt autonomous signaling (Drost et al., 2015; Matano 
et al., 2015; Onuma et al., 2013).  
 
3.2.3 BRAFV600E promotes acquisition of stem cell niche factor growth 
independency and maintenance of stemness in the organoids 
Pursuant to the above data, we investigated stem cell niche factor 
dependency of the organoids by culturing them for three weeks in five different 
media conditions including fully factor ENSW media, partially deficient media 
such as NSW, NS and N and fully deficient Base media (Figure 3.4A). The full 
support media for normal organoids contains, in addition to the Wnt activators 
(R-Spondin1 and Wnt3a), other stem cell niche growth factors such as Noggin 
and EGF (Figure 3.4B). By 5 months of growth, only BRAFCA organoids acquired 
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the property to grow in base media, which completely lacks of all four niche 
factors used to support stemness and growth of WT organoids including any of 
Wnt activators (Figure 3.4C) (Date and Sato, 2015; Sato et al., 2011; Sato et al., 
2009). Among all of our organoid cultures, the KRASCA and WT organoids 
derived at 2 months post Cre-induction are independent of EGF but require 
Wnt3a, R-spondin1 and Noggin (Figure 3.4C) to sustain their growth for three 
weeks. However, BRAFCA organoids at 2 months is independent of Wnt3a in 
addition to EGF although R-spondin1 and Noggin are required (Figure 3.4C). As 
above, at 5 months, KRASCA (KRASCA1 and KRASCA2) and wild type organoids 
(WT, BRAFEV1, BRAF EV2 and BRAF EV3) still require R-spondin1 and Noggin to 
sustain their growth and stemness (Figure 3.4C). The independent organoids 
from three BRAFCA replicates were continuously cultured in base, factor free 
media and three separate BRAFCA-IND replicates are established from the culture. 
The polypoid growth observed previously in BRAFCA organoids (Figure 3.3, C and 
D) is now even more prominent in the BRAFCA-IND organoids, indicating a 
progressive accumulation and selection of dysplastic cells in Base medium 
(Figure 3.5A). The multi-layered polypoid growth in the BRAFCA-IND fills up the 
lumen, which otherwise in WT or EV organoids consists of many dead cells 
(Figgure 3.5, A and B). 
We next find that the above niche-factor independency, and autonomous 
Wnt signaling of BRAFCA-IND organoids is due to cell intrinsic mechanisms and 
not secretion of Wnt3a from Paneth cell or Paneth-like cells in the BRAFCA-IND 
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organoids. Thus, when equal proportions of BRAFCA-IND organoids were co-
cultured for one week in Base media and ENSW media with BRAFEV or KRASCA 
organoids (Figure 3.6A), only the recombined BRAFV600E allele originating from 
BRAFCA-IND was detected in both ENSW and Base media culture (Figure 3.6B). In 
contrast, BRAFEV or KRASCA existed only in the full ENSW medium but not in 
Base media as indicated by the presence of recombined and non-recombined 
BRAFV600E alleles or the recombined KRASG12D allele in the respective co-cultures 
in ENSW media not in Base media (Figure 3.6B). Moreover, tdTomato+ BRAFCA-
IND and tdTomato- BRAFEV organoids were observed in ENSW media but in Base 
medium only tdTomato-positive BRAFCA-IND organoids survived (Figure 3.6A).  
To further pursue the conclusions that BRAFCA organoids have acquired 
autonomous Wnt-activation rendering them independent of Wnt in the medium, 
we used porcupine inhibitor IWP2 to further clarify the scenario. Palmitoylation 
of Wnt ligand by Porcupine (Porcn) is a critical step for Wnt secretion and 
subsequently action of Wnt ligands on their receptors (Chen et al., 2009). The 
IWP2 will prevent secretion of Wnts from any type of cells and their subsequent 
paracrine or autocrine action (Figure 3.7, A and B). In this experiment, the 
organoids are treated with IWP2 in NS media, which is deficient of external 
Wnt3a (Figure 3.7B). The IWP2 completely inhibit growth of WT and BRAFEV at 
low dose of 2.5mM (Figure 3.7B). KRASCA replicates are slightly resistant to 
IWP2 but their growth is inhibited more than 50% at higher dose of 10mM 
(Figure 3.7B). Two BRAFCA replicates also have partial resistance as KRASCA but 
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the other one replicate is completely resistant to IWP2 (Figure 3.7B). Moreover, 
all BRAFCA-IND replicates are completely resistant to IWP2 indicating that they 
are enriched for organoids that are completely autonomous and independent of 
external Wnt signaling.  
 
3.2.4 A single step transformation by BRAFV600E induces right-sided 
CRC phenotype forming invasive mucinous adenocarcinomas 
All the above results indicate that the BRAFCA organoids have abnormal 
and aggressive growth properties and independency to environmental signalings 
hinting that these cells are transformed by BRAFV600E alone. To test if this indeed 
is the case, we performed xenograft assay in NOD scid gamma immunodeficient 
mice (NSG). All wild type organoids, WT and BRAFEV1-3, and the KRASCA1-2 
organoids didn’t form any tumors in the NSG mice. In contrast, BRAFCA1, 
BRAFCA3, BRAFCA-IND1-3 formed tumors in all injection sites although the size of 
tumor and growth rate were variable within and between the samples (Figure 
3.8A). Grossly, the tumors were gelatinous with copious amount of mucin (Figure 
3.8B). Histologically, the tumors display features of mucinous carcinomas with 
dysplastic changes. The tumors consist of mucin filled cysts lined by dysplastic 
epithelial cells displaying piled up cells, high nuclear to cytoplasm ratio, bizarre 
looking mitotic figures and multinucleated cells (Figure 3.8B). A fair number of 
goblet cells spread between the epithelial cells. Signet rings, a pathognomonic 
feature of mucinous carcinoma, also are observed in the tumors (Figure 3.8B). 
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These morphological features are also observed in human mucinous colon 
adenocarcinomas as shown here in Figure 3.8, A and B.  
In addition, two injection sites of BRAFCA-IND1 and 3, formed tumor which 
invaded into the peritoneum. One of these xenografts also resulted in a tumor 
infiltrating the kidney capsule (Figure 3.9A). Both tumors in subcutaneous and 
kidney capsule shared the same features of dysplasia and mucinous 
characteristics (Figure 3.9C). The integrity of muscle layer between the tumors 
inside and outside was disrupted with tumor cells seeded between the muscle 
fibers (Figure 3.9 C). The ability of tumor cells to survive in blood stream and 
metastasize to distal regions is also verified by formation of xenograft tumor after 
tail vein injection of single cells of BRAFCA-IND1 (Figure 3.9B). Thus, the cells from 
BRAF mutant organoids were able to survive in the blood stream, extravasate 
from the vessel and grow as a tumor outside of the blood stream (Figure 3.9B). 
The xenograft tumor formation indicates that BRAFCA organoids are capable to 
make an invasive mucinous adenocarcinoma, which is frequently found in human 
right-sided BRAF mutant CRC (Bettington et al., 2013; Nosho et al., 2008; Pai et 
al., 2012; Song et al., 2005; Tanaka et al., 2006). Notably in the TCGA CRC 
database (Figure 3.10, A and B) BRAF mutations are strongly associated with 
mucinous adenocarcinoma in Fisher’s exact test with p value of 1.676e-06 (Figure 
3.10A) 
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3.2.5 BRAFV600E organoids promotes sustained up-regulation of 
intestinal stem cell and proliferation genes and intestinal Wnt targets 
during deprivation of all stem cell niche factors. 
To investigate how the BRAFCA organoids were able to survive without 
stem cell niche factors, gene expression profiling was performed in WT, BRAFEV, 
BRAFCA, BRAFCA-IND and KRASCA organoids grown in two different media 
conditions, ENSW and Base media for 48hr (Figure 3.11A). In ENSW media 
condition, the BRAFCA and BRAFCA-IND organoids show a very similar gene 
expression pattern as WT, BRAFEV and KRASCA organoids. This is probably due 
to prevailing activation of Wnt and others pathways by stem cell niche factors in 
ENSW media (Sato et al., 2009). In contrast, the BRAFCA and BRAFCA-IND 
organoids show very distinct gene expression pattern from WT, BRAFEV and 
KRASCA organoids in Base media. Firstly, with the gene expression pattern from 
those organoids in Base media, Gene Set Enrichment Analysis(GSEA) with 
Hallmark gene sets (Figure 3.11B) indicates that BRAFCA, BRAFCA-IND and 
KRASCA are enriched with proliferation pathways such as E2F targets, G2M 
checkpoint, mitotic spindle and DNA repair and cancer related pathways 
including Myc targets (Figure 3.11C) and Mtorc1 signaling (Table 3.1). More 
interestingly, only BRAFCA and BRAFCA-IND,organoids but not KRASCA organoids, 
are enriched for Wnt / β-catenin signaling (Table 3.1 and Figure 3.11C). To 
further delineate the expression patterns, the CoGAPS (Coordinated Gene 
Activity In Pattern Sets) algorithm was applied to the dataset to find patterns of 
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gene expression changes in the organiods with different genotypes (Figure 3.12, A 
and B) (Fertig et al., 2010; Fertig et al., 2013; Fertig et al., 2012; Fertig et al., 
2014; Speier and Ochs, 2012; Stansfield et al., 2016). Four different patterns of 
gene expression were found (Figure 3.12C). Pattern 1 contains genes up-regulated 
in ENSW media and down-regulated in Base media in WT / BRAFEV. However, 
the up-regulation of the gene remain in BRAFCA-IND and BRAFCA1 even under 
deprivation of all niche factors (Figure 3.12C) and these genes are those up-
regulated in intestinal stem cells and proliferating cells (TA cells) (Merlos-Suarez 
et al., 2011) and intestinal Wnt target genes (de Lau et al., 2011). Two important 
stem-cell marker genes, CD44 and SOX9 (Du et al., 2008; Feng et al., 2013), are 
among these genes and we verified their high levels by quantitative PCR (Figure 
3.14, A and B). Although their expression is not sustained in KRASCA and the 
other two BRAFCA replicates in Base media as in WT / BRAFEV, the extent of 
down-regulation is less than in WT / BRAFEV (Figure 3.12C). The pattern 2 has 
the opposite direction containing gene down-regulated in ENSW and up-
regulated in BASE in WT / BRAFEV (Figure 3.12C) but which remain low in 
BRAFCA-IND and BRAFCA1 during deprivation of all factors (Figure 3.12C). These 
genes are those normally up-regulated in differentiated epithelial cells (Merlos-
Suarez et al., 2011) (Figure 3.13B). Pattern 3 and 4 contain genes with high 
expression  in WT / BRAFEV (Figure 3.12C). Pattern 4 genes have high expression 
in BRAFCA-IND and low expression in WT / BRAFEV (Figure 3.12C).  
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3.2.6 BRAFV600E organoids exhibit sustained up-regulation of 
intestinal stem cell population 
In addition to the gene expression pattern outlined in the preceding 
section, increased stemness in BRAFCA-IND was also confirmed by flow cytometry 
assay for CD44, which is a stem-cell marker (Du et al., 2008; Kuhnert et al., 
2004). In organoids grown in ENSW, the CD44 positivity was highest in BRAFCA-
IND, followed by BRAFCA, KRASCA and WT (Figure 3.15 A and C). On average, 
about 39% of cells in BRAFCA-IND, 25% of cells in BRAFCA, 22% of cells in KRASCA 
and 1.6% of cells in WT were CD44 positive (Figure 3.15 A and C). Upon 
deprivation of stem cell niche factors, the number of CD44+ stem cells in BRAFCA 
and KRASCA was further decreased to 12% and 4% on average, respectively 
(Figure 3.15 B and C) and in WT, to below 1% (Figure 3.15 B and C). In contrast, 
CD44+ stem cell population in BRAFCA-IND was increased in all three replicates 
upon deprivation of the niche factors (Figure 3.15 B and C) to an average of 
around 60% in BRAFCA-IND in Base media (Figure 3.15 B and C).  Thus, the data 
above show that in contrast to the dynamic regulation of stemness and 
differentiation genes in WT, KRASCA and BRAFCA organoids in response to the 
deprivation of niche factors, expression of these genes is stably maintained in 
BRAFCA-IND in a pattern reflecting pro-stemness and anti-differentiation. 
 
3.2.7 BRAFV600E exhibit similar methylation profile as human right-
sided CRC including presence of CIMP and increased methylation of 
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genes for stemness, differentiation maintenance and regulation of the 
Wnt pathway  
Right sided human CRCs with BRAFV600E mutations frequently have an 
important epigenetic characteristic termed the gene promoter, CpG island DNA 
hypermethylation phenotype or CIMP positive (Bettington et al., 2013; Burnett-
Hartman et al., 2013; Hinoue et al., 2012; Hinoue et al., 2009; Hughes et al., 
2012; Hughes et al., 2013; Jass, 2007; Kambara et al., 2004; Kriegl et al., 2011; 
Lee et al., 2008; Nosho et al., 2008; O'Brien et al., 2006; Ogino et al., 2006; Pai 
et al., 2012; Phipps et al., 2015; Silva et al., 2014; Song et al., 2005; Sugai et al., 
2006; Tanaka et al., 2006; Toyota et al., 1999; Weisenberger et al., 2006; 
Yamamoto et al., 2012; Yang et al., 2004).  In contrast, the-left sided tumors with 
frequent KRASG12D/V mutations are associated with CIMP- and CIMP-
intermediate groups (Bettington et al., 2013; Burnett-Hartman et al., 2013; 
Hinoue et al., 2012; Hinoue et al., 2009; Hughes et al., 2012; Hughes et al., 2013; 
Jass, 2007; Kambara et al., 2004; Kriegl et al., 2011; Lee et al., 2008; Nosho et al., 
2008; O'Brien et al., 2006; Ogino et al., 2006; Pai et al., 2012; Phipps et al., 2015; 
Silva et al., 2014; Song et al., 2005; Sugai et al., 2006; Tanaka et al., 2006; 
Toyota et al., 1999; Weisenberger et al., 2006; Yamamoto et al., 2012; Yang et al., 
2004). Why the right-sided BRAFV600E tumors have CIMP and whether this 
epigenetic abnormality is a “driver versus passenger” event for evolution of these 
cancers has not been clarified. Thus we tested for methylation differences among 
the WT, KRASCA, BRAFEV, BRAFCA and BRAFCA-IND organoids. One replicate of 
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each was subjected to a genome-wide methylation analysis at 5 months after 
induction of mutations  using MBD-seq (Figure 3.16A) (Guerrero-Preston et al., 
2014). The result indicates that CIMP is a feature of our BRAF mutant organoid 
model and many of the involved genes are those that may play an essential driver 
role in cells escaping from senescence, stem cell features, lack of differentiation 
and especially Wnt autonomous signaling. Thus, as compared to WT and empty 
vector control BRAFEV organoids, there is increased DNA methylation of 
normally unmethylated promoter CpG islands of ~ 225  genes at 5 months in 
BRAFCA  organoids with even more, ~ 500 in BRAFCA-IND organoids while only 20-
50 such  genes exist in  KRASCA organoids (Figure 3.17A). KEGG gene ontology 
analysis of these genes differentially methylated in BRAFCA-IND revealed Wnt 
signaling as the second most significant pathway enriched following 
melanogenesis which is also driven by a Wnt signature (Figure 3.17B). Thus the 
sustained stem cell features and autonomous Wnt activation accompanying 
induction of BRAFV600E might well be due to epigenetic modulation of Wnt 
pathway. The methylation patterns for individual Wnt genes are shown in Figure 
3.18A with hypermethylation seen for important Wnt negative regulators, 
including Sfrp1 and 2, Hic1, Wt1, Sox7, Sox17, Frzb and Cdh2 in BRAFCA-IND 
organoids and partially in BRAFCA but not in WT and KRASCA organoids (Figure 
3.18A). All of these genes are methylated in CIMP CRC (Hinoue et al., 2012; 
Hinoue et al., 2009; Toyota et al., 1999; Weisenberger et al., 2006; Yamamoto et 
al., 2012). In addition, there is increased DNA methylation in other CIMP genes 
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such as Socs1, Gata3, Galnt4, Fzd10, Cdkn2a and Igfbp7 (Figure 3.18B). Of these, 
epigenetic suppression of Cdkn2a (Carragher et al., 2010) and Igfbp7 (Wajapeyee 
et al., 2010) were previously reported to play a critical role in escape from 
oncogene induced senescence. The methylation of these two genes in BRAFCA-IND 
correlates well with the previous reports and explains why BRAFCA-IND organoids 
may not show any signs of senescence. Lastly, very important genes which 
normally are expressed to control intestine differentiation, including Bmp4 and 
Bmpr1b are abnormally methylated as well in BRAFCA-IND organoids and partially 
in BRAFCA organoids (Figure 3.18C). As discussed in section 3.2.5 and 3.2.6, stem 
cell gene expression signature and high stem cell population characterize 
BRAFCA-IND organoids and also, partially in BRAFCA organiods and each of the 
above silenced genes may play important roles in these phenotypic features. For 
example, without Noggin added to the media, BMP4 should have induced 
differentiation through inhibition of Wnt signaling (Foulke-Abel et al., 2016; He 
et al., 2004; Mahe et al., 2015; Saxena et al., 2016; Zachos et al., 2016).  
 
3.3 Discussion 
This work shows that, unlike KRASG12D, BRAFV600E mutation drives stem 
cell niche factor independent growth and tumorigenic transformation in colon 
organoids. These properties are acquired through accumulation of DNA 
methylation in Wnt negative regulators, CIMP genes including cell cycle check 
point genes, genes that induce differentiation, and genetic mutations in Wnt 
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activators such as b-catenin. Importantly, transformation of organoids by 
BRAFV600E recapitulates human BRAF mutant tumors in terms of molecular 
changes and morphological features. Thus the data in this thesis shows that in 
the serrated pathway to colon cancers, BRAFV600E mutation alone induces and 
selects for a combination of key epigenetic and genetic alterations that lead to 
acquisition of Wnt pathway activation and stemness (Figure 3.19).  
The major observation here that BRAFV600E causes a gradual acquisition of 
Wnt independency presents novel molecular insights into the alternate or sessile-
serrated pathway to CRC. The serrated pathway has been invoked to explain non-
APC mutant CRCs which do not fit with the classical pathway model known as 
Vogelgram (Jorissen et al., 2015). While BRAF mutation is highly associated with 
cancers in the sessile-serrated pathway, APC mutations are much less frequent. 
The observation that in one step BRAFV600E is able to cause Wnt independency 
and transformation without other mutations to start with may explain why BRAF 
mutant CRCs have a tendency not to have concurrent APC mutation even though 
Wnt activation is a known characteristic of these tumors (Morkel et al., 2015; 
Murakami et al., 2015). The molecular changes we observe in the BRAFCA-IND 
organoids, especially altered epigenetic and genetic changes involved in Wnt 
activation, appears to provide a basis for how BRAFV600E results in CRC in the 
absence of starting Wnt activating mutations. In this context, the data here 
supports the study by Rad and colleagues which showed that activation of 
BRAFV600E in mouse intestine caused adenomas and carcinomas, about a third of 
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which can be attributed to mutations in Wnt pathway genes, including β-catenin 
(Rad et al., 2013). In contrast, the classical CRC pathway generally begins with 
Wnt activation by mutations in APC, followed by activation of KRAS. Previous 
studies have shown that APC knock out or knock down can make organoids 
independent to Wnt3a and R-spondin and induce them to form tumors in 
conjunction with other mutations such as activating KRAS mutation, inactivating 
p53 and SMAD4 mutations (Li et al., 2014; Matano et al., 2015). Further, a small 
group of serrated CRCs have KRAS mutations, and do not activate the Wnt 
pathway, but are dependent on inactivation of p16Ink4a/Rb pathway (Bennecke et 
al., 2010). Thus our studies in conjunction with the other studies discussed above 
shows that although activating mutations in KRAS and BRAF are key driver 
mutations of CRCs, BRAF activating mutation in the colon epithelial stem cell 
niche causes distinct epigenetic and genetic changes, the key result of which is 
Wnt activation, helping to explain the sessile-serrated route to CRC. 
The observation that BRAFV600E, but not KRASG12D, causes stem cell niche 
factor independent growth and transformation is intriguing given that both 
mediate their effect through activating the RAS-RAF-MEK signaling pathway. 
Most importantly, genome-wide DNA methylation analyses shows DNA 
methylation of normally unmethylated promoter CpG islands for ~ 225  genes at 
5 months in BRAFCA organoids with even more, ~500 in BRAFCA-IND organoids, 
while only 20-50 such  genes in  KRASCA organoids are affected as compared to 
WT organoids. Thus, this epigenetic change appears to not only evolve after 
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induction of BRAFV600E but to be further selected in BRAFCA-IND cells. 
Furthermore, the involved genes are highly represented in the CIMP+ marker 
genes for human right-sided CRC as found in TCGA analyses. The genes 
methylated in BRAFCA-IND organoids, include negative regulators of Wnt such as 
Sfrp1, Sfrp2, Hic1, Wt1, Sox7, Sox17, Frzb and Cdh2, while KRASG12D organoids 
do not show methylation at these genes. The differential effect of BRAFV600E and 
KRASG12D on inducing the epigenetic alteration is not only relevant to the 
tumorigenesis process, but also extremely important in terms of the mechanisms 
involved in methylation of the promoter CpG islands. Previous studies have 
causally implicated both KRAS (Serra et al., 2014) and BRAF (Fang et al., 2014) 
in mediating the CIMP phenotype through two different proteins, ZNF304 and 
MAFG, respectively. However, these experiments have been performed in cancer 
cell lines, which already have high level of DNA methylation. Further, our studies 
here and the inferred relation between CIMP and BRAF or KRAS mutations in 
CRCs from TCGA data and other clinical studies (Hinoue et al., 2012; Hinoue et 
al., 2009; Hughes et al., 2012; Hughes et al., 2013; Jass, 2007; Kambara et al., 
2004; Lee et al., 2008; Nosho et al., 2008; Sugai et al., 2006; Tanaka et al., 
2006; Toyota et al., 1999; Weisenberger et al., 2006; Yang et al., 2004) (Figure 
3.18B) suggest a dominant role for BRAF in inducing the CIMP phenotype. The 
exact mechanism underlying the gradual accumulation of methylation in BRAFCA 
and BRAFCA-IND, but not KRASCA organoids, need to continue to be investigated. 
Our organoid model developed here will be invaluable to study the mechanisms 
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mediating the differential effect of mutant BRAF and KRAS on modulating the 
epigenome in a natural and non-transformed cellular context rather than 
transformed cancer cells. 
Our present study has major implications in understanding and treating 
human right-sided CIMP positive CRCs. The stem cell niche factor independent 
BRAF organoids recapitulate many features of right-sided CIMP positive BRAF 
mutant CRCs. Non-APC mutant / BRAF mutant tumors tend to be mucinous 
adenocarcinoma in human (Bettington et al., 2013; Nosho et al., 2008; Pai et al., 
2012; Song et al., 2005; Tanaka et al., 2006) (Figure 3.10 A and B). Subcutaneous 
xenografting of BRAFCA and BRAFCA-IND organoids resulted in mucinous 
adenocarcinoma highlighted by signet ring and formation of mucin filled 
glandular cysts. This category of right-sided human CRCs, which also display MSI 
(microsatellite instable), have recently been shown to have increased T cell 
infiltration and better prognosis to immunotherapy (Le et al., 2015). However, 
MSS tumors with BRAF mutations have the worst prognosis (Jorissen et al., 
2015). There have been controversies over whether the increased T cell 
infiltration is due to higher number of neoantigen generated from the high 
mutational burden in BRAF mutant MSI tumors or overall cellular stress due to 
increased mutation in the MSI tumors. Our organoid model, with appropriate 
manipulations to inactivate Mlh1 to create the MSI phenotype, can be used to 
address the interaction between the immune system and the tumor cells in an 
immunocompetent syngeneic xenograft or orthotopic transplantation model. 
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Finally, the ability for BRAFV600E to cause transformed phenotype in the 
absence of a microenvironment deserves special mention. The original inducible 
construct for our model was first engineered for internal expression throughout 
the mouse intestine and we induced the mutation in this setting as well. In 
contrast to the results in our organoid model, with induced transformation in 2-5 
months, we observed only hyperplastic growth in the colon epithelium up to 
about 6 months after BRAFV600E induction in LGR5+ stem cells or CDX2+ 
colonocytes. The mice develop severe skin lesions and other tumors beyond this 
point so they could not be monitored further. In the BRAF mutation mouse 
model, it takes a prolonged period of greater than a year to form colon adenomas 
(Rad et al., 2013). Thus the native colonic setting of the crypts and the 
microenvironment appears, at least initially to be anti-tumorigenic, and this fact 
accentuates our findings for the intrinsic pathway signaling and tumorigenesis of 
BRAFV600E in the ex vivo organoid setting. Key questions thus will be how the 
microenvironment prevents tumorigenesis. It is already known that stroma can 
have suppressive role in tumorigenesis that can be mediated through Hedgehog 
signaling pathway (Shin et al., 2011; Vaegler et al., 2012) and other pathways. The 
accentuated tumorigenesis we see in our organoid culture could be due to the 
absence of stromal interaction. The effect of interaction between epithelial cells 
and stroma can be investigated with the organoid model in conjunction with an 
organoid / stroma co-culture model (Figure 3.20). 
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3.4 Material and Methods 
3.4.1 Mouse breeding and animal experimentation 
All animal experiments were implemented in accordance with an animal 
protocol approved by the Johns Hopkins University Animal Care and Use 
Committee (Protocol# MO10M388). All the mice were housed in Helicobacter 
negative and SPF (Specific Pathogen Free) environment.  
Homozygous tdTomato reporter (B6;129S6-Gt(ROSA)26Sortm9(CAG-
tdTomato)Hze/J) mouse was bred with heterozygous inducible BRAF mouse 
(B6.129P2(Cg)-Braftm1Mmcm/J) or heterozygous inducible KRAS mouse 
(B6.129S4-Krastm4Tyj/J) to generate mice that are heterozygous BRAF with 
heterozygous tdTomato reporter, heterozygous KRAS with heterozygous 
TomatoRed reporter and wild type with heterozygous TomatoRed. 
 
3.4.2 Isolation of crypt cells from colon 
Male mice from each genotype between the age of 35 days and 40 days 
were euthanized by carbon dioxide and subjected to a necropsy. The first 2 cm of 
proximal colon is collected from the mice. The collected colons were washed 5 
times with sterile Complete Chelating Solution (CCS: 5.6mM Na2HPO4, 8mM 
KH2PO4, 96.2mM NaCl, 1.6mM KCl, 43.4mM Sucrose, 54.9mM D-Sorbitol and 
0.5mM DL-dithioteritol and incubated in sterile CCS with cocktail of antibiotics: 
Primocin (Invivogen ant-pm-1) and Normocin (Invivogen ant-nr-1) for 30 
minutes in 4°C. The clean proximal colons were incubated in CCS with 2mM 
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EDTA for 20 minutes at 37°C to release crypt from the tissue. After incubation, 
the crypts on the proximal colon were gently scraped with cell scraper to collect 
crypts. The crypts were collected with CCS with EDTA in 15ml tubes and the 
tubes were centrifuged at 300g for 10 minutes. Subsequently, the crypt pellets 
were washed with CCS with cocktail of antibiotics for 4 times by repeated 
resuspension and centrifugation.  After the serial washing, the crypts were 
resuspended in growth factor reduced phenol red free Matrigel® (Corning® 
#356231) and plated on regular cell culture plates. 
 
3.4.3 Organoids culture 
The plated organoids were cultured with ENSW culture media made of 
50% of Wnt3a conditioned media, 20% of R-Spondin conditioned media, 20% of 
Advanced DMEM/F12 (Invitrogen® 12634-010) with 1% Pen strep® 
(ThermoFisher® 15140148), 10mM HEPES, 2mM L-glutamine and B27 
(Invitrogen® 17504044), 10% of Noggin conditioned media and 100ng/ml of 
EGF(R&D systems 236-EG-200). The conditioned media for Wnt3a, R-Spondin 
and Noggin were made as described previously (Matano et al., 2015; Sato et al., 
2011; Sato et al., 2009). NSW media was made with 50% of Wnt3a conditioned 
media, 20% of R-Spondin conditioned media, 20% of Advanced DMEM/F12 
(Invitrogen® 12634-010) with 1% Pen strep® (ThermoFisher® 15140148), 10mM 
HEPES, 2mM L-glutamine and B27 (Invitrogen® 17504044), 10% of Noggin 
conditioned media. NS media was made with 50% of DMEM with 10% FBS, 20% 
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of R-Spondin conditioned media, 20% of Advanced DMEM/F12 (Invitrogen® 
12634-010)  with 1% Pen strep® (ThermoFisher® 15140148), 10mM HEPES, 
2mM L-glutamine and B27 (Invitrogen® 17504044), 10% of Noggin conditioned 
media. N media was made with 50% of DMEM with 10% FBS, 20% of Advanced 
DMEM/F12 with 1% Pen strep® (ThermoFisher® 15140148), 10mM HEPES and 
2mM L-glutamine, 20% of Advanced DMEM/F12 (Invitrogen® 12634-010)  with 
1% Pen strep® (ThermoFisher® 15140148), 10mM HEPES, 2mM L-glutamine and 
B27 (Invitrogen® 17504044), 10% of Noggin conditioned media. Base media was 
made with 50% of DMEM with 10% FBS, 30% of Advanced DMEM/F12 with 1% 
Pen strep® (ThermoFisher® 15140148), 10mM HEPE and 2mM L-glutamin, 20% 
of Advanced DMEM/F12 (Invitrogen® 12634-010)  with 1% Pen strep® 
(ThermoFisher® 15140148), 10mM HEPES, 2mM L-glutamine and 
B27(Invitrogen® 17504044). 
 
3.4.4 Subcloning of lentivirus plasmid and packaging of lentivirus 
Puromycin resistance gene in Puro.Cre empty vector (Addgene #17408) 
was replaced by hygromycin resistance gene PCR amplified from pBABE-hygro-
hTERT (Addgene #1773) using primer listed below (Hyg F and R) by Gibson 
Assembly® cloning kit (NEB® #E5510S) generating Lenti-cre vector. 
Subsequently, Cre in the Lenti-cre vector was deleted by Gibson Assembly® 
cloning kit generating Lenti-empty vector using primers listed below (Cre 
deletion F and R).  
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Hyg F: TAACGCGCTAGCAAAGATGAAAAAGCCTGAACTCAC 
Hyg R: GTAGAATGCGGCCGCCTATTCCTTTGCCCTCGG 
Cre deletion F : CCGTAACCTGGATAGTGAAAC 
Cre deletion R : CCTTCCTCTTCTTCTTGGG 
Lentivirus was produced in Lenti-X™ 293T cell line transfected with 
Packaging vectors and Lenti-cre or Lenti-empty mixed with Xfect™ polymer. 
72hr after the transfection, the media is collected and concentrated using Lenti-
X™ concentrator.  
 
3.4.5 Transduction of organoids with lentivirus 
Organoids were collected from Matrigel® (Corning® #356231) using Cell 
Recovery solution (Corning® #354253). Organoids were broken into small piece 
of cells by repeated pipetting. The small pieces of cells were digested by 2U/ml of 
Dispase I for 20 minute at 37’C. Matrigel® is spread on the 12 well surface and 
the plate is incubated at 37°C to polymerize for 10 minutes. The digested 
organoids are mixed with virus and 8ug/ml Polybrene® (Sigma-Aldrich® 
#107689) in ENSW organoid culture media and plated on the solidified 
Matrigel®. After 24 hour, the media is removed and Matrigel® is spread on the 
organoids.    
 
3.4.6 DNA/RNA isolation 
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Organoids were collected from Matrigel® (Corning® #356231) using Cell 
Recovery solution The collected organoids were broken into small piece of cells 
by repeated pipetting and incubated in 15ml ice cold media for 30min letting live 
cells precipitate. Live cells in bottom 3ml were recovered and mixed again with 
12ml of media for second precipitation. After second precipitation, bottom 2ml of 
the media was collected and centrifuged at 1,000g for 1minute to make a pellet. 
From the pellet, DNA/RNA was extract using Allprep kit mini or micro (Qaigen) 
 
3.4.7 Recombination specific PCR and genotyping 
Mouse genotypes were determined by standard PCR of tail DNA. BRAF 
genotype and recombination is determined by a primer set of BRAF Fwd (5′-TGA 
GTA TTT TTG TGG CAA CTG C-3′) and BRAF Rev ( 5′-CTC TGC TGG GAA AGC 
GGC-3′). 185base pair, 308 base pair and 335 base pair fragments are generated 
from wild type allele, non-recombined mutant allele and recombined mutant 
allele respectively (Dankort et al., 2007). KRAS genotype is determined by PCR 
with KRAS mt Fwd (5′-CCA TGG CTT GAG TAA GTC TGC-3′) and KRAS mt 
Rev(5′-CGC AGA CTG TAG AGC AGC G-3′). Recombination of KRAS mutant 
allele is determined by a PCR with KRAS 1(5′-GTC TTT CCC CAG CAC AG TGC-
3′) and KRAS 2(5′-AGC TAG CCA CCA TGG CTT GAG TAA GTC TGC A-3′). 
Recombined mutant allele generates 650base pair long fragments and wild type 
allele generates 622 base pair fragments with this PCR. 
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3.4.8 Organoid growth assay by CellTiter-Glo 3D 
The organoids were collected using Cell Recovery solution (Corning 
#354253). The same volume of CellTiter-Glo3D® (Promega #G9681) was added 
to organoids suspension and mixed by vortexing at high speed for 5min. Then, 
the mixture was incubated for 25min at room temperature. The mixture was 
distributed in three wells of dark 96 well plates and its luminescence was 
measured by plate reader (POLARstar® Omega by BMG LABTECH) 
 
3.4.9 Quantification of cell number for xenograft assay 
The organoids were recovered from the Matrigel using Cell Recovery 
solution (Corning #354253). The organoids were disrupted and washed in the 
media 2 times to get rid of dead cells. Then, the fragmented organoids were 
serially diluted and each dilution was separated into two wells, one for CellTiter-
Glo3D assay and the other for Quant-iT PicoGreen® ds DNA assay. The 
luminescence of CellTiter-Glo3D assay and fluorescence of Quant-iT PicoGreen® 
ds DNA assay were measured by plate reader (POLARstar® Omega by BMG 
LABTECH). A correlative standard curve between these two values in the serial 
dilution of the organoids was generated. Based on the size of mouse genome (2.8 
x 109 base pairs), the amount of DNA per diploid genome is about 6 pg. Thus 
based on the amount of DNA, the number of cells were extrapolated for the 
standard curve. For organoids that were to be implanted, an aliquot of the 
organoids was fragmented as above and used to estimate the cell numbers using 
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the CellTiter-Glo3D assay and the standard curve above. Then proportions of 
intact organoid aliquots amounting to equal cell numbers of the different genetic 
backgrounds were used for implantation as described below.  
 
3.4.10 Xenograft implantation 
The organoids were recovered from the Matrigel using Cell Recovery sol 
(Corning #354253) without disrupting the structures. Then, using a portion of 
the organoids, CellTiter-Glo3D assay is performed. Using the formulation 
between CellTiter-Glo3D and cell number, cell number was estimated. Based on 
the estimation, 0.5 million cells were injected subcutaneously with 16G needle to 
minimize disruption of the organoid 3D structure in male NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (NSG) (JAX™) with Matrigel. Injection sites were 
examined every week for tumor growth. The volume of the tumors estimated by 
ellipsoid volume formula. 
 
3.4.11 Flow cytometry 
Organoids were collected from Matrigel using Cell Recovery solution 
(Corning #354253). Organoids were broken into small piece of cells. The small 
piece of cells were digested by 2U/ml of Dispase I (Sigma #D4818) for 20 minute 
at 37°C. Digested organoids were filtered through 70um cell strainer. The single 
cells were stained with CD44 antibody (ThermoFisher #A161693) and 200ng/ml 
of DAPI for live/dead cell staining. The cells were analyzed by flow cytometry 
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using a DakoCytomation MoFlo at flow cytometry core of Johns Hopkins School 
of Public Health. 
 
3.4.12 Quantitative RT-PCR 
RNA was converted to cDNA using qscript (Quanta #95048-025) 
following the standard protocol. Quantitative PCR reactions were run on the 
cDNA samples with triplicate technical replicates using Taqman probe assays, 
Mm99999915_g1 for GAPDH, Mm00448840_m1 for Sox9 and Mm01277161_m1 
for Cd44. GAPDH was used as an endogenous control. It is selected based on 
stable gene expression pattern in gene expression array.  
 
3.4.13 Gene expression microarray 
For genome-wide gene expression analysis, we carried out gene expression 
array at the Sidney Kimmel Comprehensive Cancer Cencer (SKCCC) Microarray 
Core at the Johns Hopkins University. Breifly, around 400ng of total RNA was 
reverse-transcribed into cDNA by MMLV-RT using oligo dT primer. Then from 
the cDNA, labeled cRNA was generated through in vitro transcription by T7 RNA 
polymerase in presence of labeled by Cyainine-3 labeled CTP (Perkin Elmer). The 
labeled cRNA was purified using Rneasy mini kit (Qiagen). 825ng of each Cy3-
labeled cRNA was hybridized to Agilent mouse GF 4x44K V2 microarray 
(G4846A) at 65ºC for 17 hours. Then, the arrays were scanned by an Agilent 
G2565 scanner.   
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Expression data were analyzed in the R/Bioconductor environment using 
the limma package (PMID:25605792). Briefly, expression data was normalized 
by quantile normalization, and the probe level information was extrapolated to 
gene level information by estimating the medial of all probes corresponding to 
each gene. These gene level values were used in COGAPS analysis as described 
below. 
 
3.4.14 Coordinated Gene Activity in Pattern Sets (CoGAPS) analysis 
For genome-wide gene expression pattern analysis, we carried out 
CoGAPS analysis in collaboration with Elana Fertig as described previously 
(Fertig et al., 2010; Fertig et al., 2013; Fertig et al., 2012; Fertig et al., 2014; 
Speier and Ochs, 2012). With the list of genes in the patterns, we performed gene 
set enrichment using a permutation test in the CoGAPS gene set statistic (Fertig 
et al., 2010; Fertig et al., 2013; Fertig et al., 2012; Fertig et al., 2014; Speier and 
Ochs, 2012) to associate CoGAPS patterns with pathways. We further performed 
clustering analysis of genes determined to be uniquely associated with each 
pattern through a “PatternMarker” statistic. Specifically, we computed the 
Euclidean distance between the elements of the P matrix for a given pattern and 
the elements of the A matrix for a given gene. In order to account for the varying 
magnitude of expression across genes, the rows of both the A and P matrix are 
scaled to have a maximum of one. The genes were ranked within each meta-
pathway by increasing distance with from its lp-norm. Unique sets of marker 
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genes were then generated by thresholding these rankings by the first gene to 
have a lower ranking, i.e. better fit to, a different meta-pathway. 
 
3.4.15 Methyl-CpG binding domain sequencing (MBD-seq) 
For genome-wide DNA methylation analysis, we carried out MBD-seq as  
described previously (Bock et al., 2010; Harris et al., 2010; Sinclair et al., 2015), 
but with significant modifications at the SKCCC Experimental and 
Computational Genomics Core at the Johns Hopkins University. Briefly, 100 ~ 
200 ng of genomic DNA was sonicated to an average size of 200 ~ 400 bp and 
subsequently methylated DNA fragments were enriched using modified MBD 
polypeptides immobilized on protein A magnetic beads (NEB, EpiMark 
Methylated DNA Enrichment Kit) according to the manufacturer’s protocol. Then, 
the enriched DNA fragments were eluted and prepared as barcoded next 
generation sequencing libraries using the ThruPlex DNA library preparation kit 
(Rubicon Genomics) according to the supplied protocols. The libraries were then 
sequenced by massively-parallel 50-bp single-end sequencing on an Illumina 
HiSeq 2500 in rapid run mode. Reads were aligned to the mm10 mouse reference 
genome using bowtie2 (Langmead and Salzberg, 2012) and duplicated reads were 
removed. For identifying differential methylated CpG island promoters, the data 
was normalized using TMM normalization (Trimmed Mean of M-values) 
(Robinson and Oshlack, 2010). After normalization, the sum of MBD-seq counts 
for each promoter region with CpG islands and without CpG island was 
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computed. Promoters with CpG islands are defined as any promoter TSS regions 
within 500bp from an annotated CpG island (downloaded from UCSC). Fisher 
test comparing the promoter regions in the test data set (BRAFCA, BRAFCA-IND or 
KRASCA) with that in WT (Bock et al., 2010).  Promoters that showed an 8-fold 
change in read counts and with a Benjamini & Hochberg corrected p-value < 0.05 
were identified as significantly differential methylated promoters.  
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TGF_BETA_SIGNALING 0.5048309 0.64634794 1 
ANGIOGENESIS 0.5347222 0.6647371 1 
WNT_BETA_CATENIN_SIGNALI
NG 0.59951454 0.6888516 1 
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NOTCH_SIGNALING 0.07307692 0.03790747 0.511 
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ANGIOGENESIS 0.16458334 0.11320952 0.891 
GLYCOLYSIS 0.29299363 0.3629813 0.999 
TGF_BETA_SIGNALING 0.4217119 0.4582001 1 










E2F_TARGETS 0 0 0 
G2M_CHECKPOINT 0 0 0 
MYC_TARGETS_V1 0 0 0 
MYC_TARGETS_V2 0 0 0 
MITOTIC_SPINDLE 0 8.75E-05 0.001 
UNFOLDED_PROTEIN_RESPON
SE 0 4.06E-04 0.004 
DNA_REPAIR 0 3.48E-04 0.004 
WNT_BETA_CATENIN_SIGNALI






7 0.02380177 0.308 
NOTCH_SIGNALING 0.15481171 0.08769937 0.798 
ANGIOGENESIS 0.4311377 0.50919443 1 
CHOLESTEROL_HOMEOSTASIS 0.86021507 0.96530354 1 
TGF_BETA_SIGNALING 0.92339545 0.9672655 1 
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Table 3.1 List of Hallmark gene sets that are highly enriched in 
KRASCA, BRAFCA and BRAFCA-IND compared to WT 
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Figure 3.1 Modeling of right-sided CRCs with proximal colon 
organoids from genetically modified mouse  
(A-C) Schematic diagram showing genetic composition of KRASG12D inducible 
mouse, BRAFV600E inducible mouse and inducible tdTom mouse. Genetic 
structures after cre induction are also displayed. The “Exon1*” stands for 
KRASG12D allele. The “Exon18*” stands for BRAFV600E allele. Arrows stands for 
PCR primers. (D) Summary of the mouse genotypes of BRAF+/LSL, KRAS+/LSL and 
WT (E) Schematic diagram of anatomic location where the colon organoids were 
isolated. (D) Schematic diagram of the lentiviral constructs. Cre-NLS (nuclear 
localization signaling) is driven by mPGK (mouse phosphoglycerate kinase-1) and 
hygromycin resistance gene (Hyg) is driven by human ubiquitin C promoter 
(Ubc). 
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Figure 3.2 BRAFV600E and KRASG12D induce organoids to form 
spheroid 
(A-D) Upon induction of BRAFV600E and KRASG12D, organoids start to form 
spheres. WT and BRAFEV didn’t undergo morphological changes maintaining the 
conventional morphology of organoids with crypt-like buds growing outward. (E) 
Quantification of sphere formation in each organoids. All BRAFCA and KRASCA 
organoids showed increased number of sphere formation compared to WT and 
three BRAFEV controls.  
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Figure 3.3 BRAFV600E and to a lesser extent, KRASG12D induce 
organiods to manifest spheroid formation with inward polypoid 
growth 
(A-B) H&E histology section and phase contrast image of wild-type organoids. 
The organoids consist of central cystic body of single layer of epithelial cells and 
outward crypt-like budding structure (wide triangle arrowhead). (C-D) H&E 
histology section and phase contrast image of BRAFCA. The organoids showed 
inward budding structure (narrow triangle arrowhead) in the central cystic body 
and dysplastic changes such as high nuclear to cytosol ratio. (E-F) H&E histology 
section and phase contrast image of KRASCA. The organoids are forming 
spheroids consisting of single layer of epithelial cells. Occasionally, KRASCA 
organoids also have inward growth. 
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Figure 3.4 Only BRAFV600E drives acquisition of stem cell niche factor 
independency 
(A) Schematic diagram of niche factor dependency assay. Each organoid clone 
was grown in five different media conditions, full factor ENSW, partially deficient 
media NSW, NS and N and fully deficient media Base media for one week and 
their growth was quantified by CellTiter-Glo assay using half of the organoids in 
each well. The other half was plated for the subsequent culture and growth 
quantification for another two weeks. (B) Summary of media conditions. “+” 
means addition of the factor. “-“ means deficiency of the factor. (C) Heatmap 
showing relative growth of each organoids in different media conditions in three 
weeks. Relative growth rates for each condition are calculated in comparison to 
ENSW media condition. The green color indicates equivalent growth as in ENSW. 
The red color indicates no growth. Only the three BRAFCA replicates grown for 5 
months (5M) were able to sustain growth in all media conditions including Base 
media. The continuing culture (dotted arrow) of the BRAFCA replicates in Base 
media established independent organoids BRAFCA-IND1-3. (“-2M” indicates 
organoids that had been cultured for 2 months after induction. “-5M” indicates 
organoids that had been cultured for 5 months after induction.) 
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Figure 3.5 Niche factor independent BRAFCA organoids (BRAFCA-IND) 
manifest augmented polypoid growth and dysplasia 
(A-B) H&E histology section and phase contrast image of BRAFCA-IND.  The 
organoids manifest inward multilayer growth (double simple arrowhead) and 
augmented dysplastic features. 
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Figure 3.6 (continued) 
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Figure 3.6 The niche factor independency of BRAFCA-IND organoids are 
not due to increased secretion of niche factors by the organoids 
(A) Schematic diagram of co-culture experiment. BRAFCA-IND organoids were 
mixed with BRAFEV or KRASCA and the mixed organoids were separated into two 
wells to grow in ENSW and Base for one week. After one week, the co-cultures 
were examined by mutant specific PCR and fluorescence microscope. (B) Mutant 
specific PCR to examine survival of each organoid types in the culture. The rec`-
BRAFV600E band, the non-rec-BRAF band and the rec`-KRASG12D band indicate 
the presence of BRAFCA-IND1-2, BRAFEV1-2 and KRASCA2, respectively. Only the 
rec`-BRAFV600E originated from BRAFCA-IND was detected in both ENSW and Base 
media. The non-rec-BRAF from BRAFEV and rec`-KRASG12D from KRASCA were 
detected only in full factor ENSW media not in Base media. (C) Fluorescence 
microscope images of co-cultures of BRAFCA-IND with BRAFEV in ENSW and Base 
media. BRAFCA-IND organoids are red-fluorescent due to expression of tdTomato 
and BRAFEV are non-fluorescent. In ENSW media, both fluorescent BRAFCA-IND 
and non-fluorescent BRAFEV survived. However, in Base media, only fluorescent 
BRAFCA-IND clones survived. (D) One week culture of BRAFEV organoids in Base 
media showed complete disintegration of BRAFEV organiods in absence of the 
niche factors.   
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Figure 3.7 BRAFCA-IND organiods are resistant to Porcupine inhibitor 
IWP2 
(A) Schematic diagram of post-translational processing of Wnt ligands. Wnt 
proteins are palmitoylated by Porcupine and transported to the cis-Golgi network 
to be secreted outside. IWP2 inhibits palmitoylation of Wnt by Porcupine and 
therefore blocks secretion of Wnt. (B) Heatmap showing growth of each organoid 
in response to IWP-2, a Porcupine inhibitor in NS media. Relative growth rates of 
oragnoid at each IWP-2 concentration are calculated in comparison to the growth 
in DMSO treatment and are displayed as green for no growth inhibition and red 
for complete growth inhibition. The growth of WT and BRAFEV was completely 
inhibited at as low as 2.5mM dose. However, the growth of KRASCA replicates was 
not completely inhibited although their growth was compromised. One of 
BRAFCA replicates, BRAFCA1 was completely resistant to IWP2 and the other two, 
BRAFCA2-3 showed partial resistance to IWP2. All three BRAFCA-IND replicates 
showed complete resistance to IWP2.  
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Figure 3.8 A single step transformation by BRAFV600E induces right- 
sided CRC phenotype 
(A) Growth curve of xenograft tumors. None of WT and KRASCA forms tumors. 
All the implantations using BRAFCA-IND form tumors. Two replicates of BRAFCA 
also form tumors as well. (B) Gross morphology of BRAFCA_IND tumor. The 
tumors .(white triangle) were gelatinous with copious amount of mucin. (C) 
Histology of human mucinouse adenocarcinoma from TCGA database (TCGA-
AA-3877). The tumor largely consists of mucin (*) filled cysts lined by piled up 
(barbed arrowhead) dysplastic cells. Occasionally, cells with a large vacuole 
(signet ring cell) present (simple arrow). (D) Histology of xenograft tumors 
(BRAFCA-XT). The tumors consist of mucin (*) filled cysts lined by piled up 
dysplastic epithelial cells (barbed arrowhead) displaying high nuclear to 
cytoplasm ratio (double simple arrowhead), bizarre looking mitotic figures 
(narrow triangle arrowhead) and multinucleation (wide triangle arrowhead). 
Occasionally, signet ring cells (simple arrowhead) are observed. 
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Figure 3.9 The transformed BRAFV600E organoids are invasive and 
metastatic 
(A) Gross morphology of invading tumor (black triangle) (BRAFCA-IND1). The 
organoids invaded to the peritoneum and grew as a tumor in the kidney capsule. 
(B) Gross morphology of metastatic tumor (white arrow) (BRAFCA-IND1). The 
organoids were digested into single cells and one million cells were injected into 
tail vein of NSG mice. The cells injected into blood stream survived and formed 
xenograft tumors. (C) Histology of invading tumors. Tumors implanted in 
subcutaneous space (white triangle) invaded through peritoneal muscle layer and 
grew as a tumor in kidney capsule (black triangle). Occasionally, the tumor cells 
were observed in space between muscle layers (black and white barbed 
arrowhead) showing evidence of invasiveness. 
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Figure 3.10 BRAF mutation is highly associated with mucinous 
adenocarcinoma histopathology type 
(A) Contingency table between BRAF mutation status and tumor histopathology 
type (mucinous vs non-mucinous adenocarcinoma) (B) Contingency analysis 
between BRAF mutation status and tumor histopathology type (mucinous vs 
non-mucinous adenocarcinoma). BRAF mutation is highly associated with 
mucinous CRC. 
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Figure 3.11 Only BRAFV600E induces Wnt / beta-catenin pathway in 
niche factor deficient media 
(A) Schematic diagram of experiment design for gene expression microarray and 
flow cytometry analysis. WT, BRAFEV, BRAFCA, KRASCA and BRAFCA-IND were 
plated in two well separately and were grown in ENSW media and BASE media 
for 48hr. After 48hr, the organoids were harvested for gene expression 
microarray and flow cytometry. (B) Schematic diagram of GSEA analysis. The 
gene expression patterns of BRAFCA, BRAFCA-IND and KRASCA are compared to 
those of WT and BRAFEV. (C) Both BRAFV600E and KRASG12D induce Myc targets. 
However, only BRAFV600E but not KRASG12D, induces Wnt / beta-catenin pathway 
in niche factor deficient media. 
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Figure 3.12 The CoGAPs pattern analysis discovered four different 
patterns of gene expression in the different types of organoids 
(A) Schematic diagram of experiment design for gene expression microarray and 
flow cytometry analysis. It is the same as in Figure 3.12. (B) Schematic diagram of 
CoGAPS analysis. CoGAPS algorithm is used to recognize agnostically patterns of 
gene expressions of the different organoids in ENSW and Base media. In each 
pattern, gene set enrichment analysis was done to discover specific pathways 
involved. (C) Heatmap of gene expression patterns. CoGAPS algorithm 
discovered four different patterns of gene expression. The pattern 1 genes are 
those up-regulated in ENSW media and dow-regulated in Base media in WT / 
BRAFEV. However, their expression are sustained high in BRAFCA-IND. Although 
their expression are not sustained in KRASCA and BRAFCA in Base media as in WT 
/ BRAFEV, the extent of down-regulation is less than in WT / BRAFEV. The 
pattern 2 has the opposite direction. The genes in the pattern 2 are down-
regulated in ENSW and up-regulated in BASE in WT / BRAFEV. However, their 
expression are sustained low in BRAFCA-IND. Their expression in KRASCA and 
BRAFCA are also up-regulated but to a lesser extent than in WT / BRAFEV. The 
pattern 3 and 4 are genes that have genotype specific changes. Pattern 3 genes 
have high expression in WT / BRAFEV. Pattern 4 genes have high expression in 
BRAFCA-IND and low expression in WT / BRAFEV.  
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Figure 3.13 BRAFV600E promotes sustained up-regulation of intestinal 
stem cell and proliferation genes and intestinal Wnt target genes even 
upon deprivation of all niche factors 
(A) Pattern 1 is enriched for intestinal Wnt target genes and genes that are 
upregulated in intestinal stem cells and proliferating cells (TA cells). (B) Pattern 
2 is enriched with genes upregulated in differentiated epithelial cells (C-D) 
Pattern 3 and 4 are enriched with differentiation genes. 
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Figure 3.14 Sustained up-regulation of intestinal stem cell markers, 
CD44 and Sox9 in BRAFCA-IND organoids 
(A-B) Quantitative RT-PCR results of CD44 and Sox9. Ct values were normalized 
to GAPDH and fold changes in Base media culture compared to ENSW media 
were calculated. Grey color represents for WT / BRAFEV, cadetblue for BRAFCA, 
aquamarine for BRAFCA-IND and brown for KRASCA. 
CHAPTER 3. SINGLE-STEP INDUCTION OF RIGHT-SIDED COLON CANCER 




CHAPTER 3. SINGLE-STEP INDUCTION OF RIGHT-SIDED COLON CANCER 
PHENOTYPE BY BRAFV600E THROUGH ACQUIRED WNT ACTIVATION 
 
	 103	
Figure 3.15 (continued) 
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Figure 3.15 (continued) 
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Figure 3.15 Sustained up-regulation of intestinal stem cells (CD44+) 
in BRAFCA-IND organoids 
(A) Flow cytometry analysis for CD44 positive stem cells in organoids in ENSW 
and Base media. WT and BRAFEV organoids consistently have the lowest number 
of CD44 positive stem cells in ENSW media. KRASCA and BRAFCA have higher 
number than WT / BRAFEV but less than BRAFCA-IND. 48 hour deprivation of the 
niche factors reduces CD44 positive stem cells significantly in WT, BRAFEV, 
KRASCA and BRAFCA. However, the CD44 positive stem cells number is increased 
in all replicates of BRAFCA-IND. (C) WT and BRAFEV organoids consistently have 
the lowest number of CD44 positive stem cells in ENSW media. KRASCA and 
BRAFCA have higher number than WT / BRAFEV but less than BRAFCA-IND. 48 
hour deprivation of the niche factors reduces CD44 positive stem cells in WT, 
BRAFEV, KRASCA and BRAFCA. Only the reduction in WT / BRAFEV is statistically 
significant. However, the CD44 positive stem cells number is increased in all 
replicates of BRAFCA-IND. BRAFCA-IND replicates have higher number of stem cells 
compared to WT / BRAFEV in both full media and deprivation media (Base) with 
a statistical significance. 
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Figure 3.16 Schematic diagram Methyl CpG binding domain (MBD) 
DNA methylation sequencing 
(A) Schematic diagram Methyl CpG binding domain (MBD) sequencing. The 
genomic DNA is sheared first and denatured. Then short single strands of DNA 
with CpG methylation are pulled down with Methyl CpG binding domain (MBD). 
The pull-down DNA strands are sequenced and aligned in the genome. 
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Figure 3. 17 
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Figure 3.17 BRAFV600E induces more differential DNA methylation 
than KRASG12D preferentially in Wnt pathway genes 
(A) Graph showing differential DNA methylation in BRAFCA, BRAFCA-IND, KRASCA 
compared to WT. There is higher number of methylated genes in BRAFCA-IND 
compared to KRASCA. (B) KEGG gene ontology analysis revealed preferential 
methylation change in melanogenesis and Wnt signaling in BRAFCA-IND.   
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Figure 3.18 BRAFV600E induces differential DNA methylation at the 
promoter CpG islands of Wnt negative regulators and CIMP marker 
genes 
(A) Representative CpG island promoter regions of Wnt negative regulators. All 
of regions have an increase of DNA methylation at their promoter CpG island in 
BRAFCA-IND and partially in BRAFCA implicating epigenetic silencing of Wnt 
negative regulators. (B) Representative CpG island promoter regions of CIMP 
genes. The regions have increased DNA methylation in BRAFCA-IND and partially 
in BRAFCA. (C) Representative CpG island promoter regions of differentiation 
genes. Promoter CpG islands of those genes are methylated in BRAFCA-IND and 
partially in BRAFCA implicating suppression of differentiation signaling in the 
organoids.  
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Figure 3.19 A single-step induction of right-sided CRC phenotype by 
BRAFV600E through acquired Wnt activation induced by accumulation 
of DNA methylation 
(A) Upon induction of BRAFV600E, the organoids accumulate DNA methylation on 
promoter CpG island of Wnt negative regulators and CIMP genes including cell 
cycle checkpoint genes. The accumulation of DNA methylation on those regions, 
in turn, induces niche factor independency through autonomous Wnt activation 
and sustained stemness. The niche factor independent organoids are fully 
transformed to form xenograft tumors which recapitulate human right-sided 
BRAF mutant tumors in terms of histopathology and DNA methylation patterns. 
However, induction of KRASG12D is not sufficient to make these changes and full 
transformation.     
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Figure 3.20 Interaction between organoids and stromal fibroblast can 
be modeled with the current BRAFV600E mutant organoids 
(A) Stromal fibroblast are reported to have a intensive interaction with epithelial 
cells through Hippo, Hedgehog and other signaling. The interaction can be 
modeled and studied by co-culturing our BRAFV600E mutant organoids with 
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